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ABSTRACT 
 
 Blood-brain barrier (BBB) disruption is the hallmark feature of the secondary injuries 
that occur following traumatic and ischemic brain injuries. Microvascular hyperpermeability 
that occurs consequently leads to vasogenic edema and elevated intracranial pressure. 
Structurally, the BBB is comprised of the brain endothelial cells and the tight junction between 
them formed by the tight junction proteins (TJPs). Zonula occludens-1 (ZO-1) is an important 
membrane-bound scaffolding TJP that links transmembrane TJPs to intracellular actin 
cytoskeletal assembly.  
 Studies indicate that adenosine triphosphate (ATP) that is released into the extracellular 
space following trauma binds to and activates the purinergic receptor (P2X7R), leading to the 
production of interleukin-1β (IL-1β); which in turn is shown to activate various downstream 
proteases. Matrix metalloproteinase-9 (MMP-9) and calpains are proteases known to induce 
BBB breakdown. However, the mechanisms by which ATP and IL-1β induce BBB dysfunction 
and hyperpermeability and the involvement of proteases in this process are vastly unknown. We 
hypothesize that ATP and IL-1β-induced BBB dysfunction and hyperpermeability occurs via 
P2X7R and /MMP-9/calpain-mediated pathways, respectively. And thus, P2X7R/MMP-
9/calpain inhibitions play an important role in mediating BBB dysfunction and 
hyperpermeability following traumatic injuries in brain. 
The results from these studies demonstrate that MMP-9/calpain inhibition attenuated 
IL-1β-induced monolayer hyperpermeability, f-actin stress fiber formation, and loss of ZO-1/TJ 
integrity and enhanced MMP-9/calpain activity in RBMECs. However, IL-1β treatment did not 
alter intracellular calcium levels, total number of viable cells, total ZO-1 protein, and mRNA 
expression. Purinergic receptor (P2X7R) inhibition attenuated Bz-ATP (potent agonist of
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P2X7R)-induced endothelial cell hyperpermeability, loss of ZO-1/TJ integrity and f-actin stress 
fiber formation. Although Bz-ATP treatment reduced ZO-1 protein expression, it did not alter 
total number of viable cells or ZO-1 mRNA expression in vitro. Melatonin (a pineal hormone 
with MMP-9 inhibitory properties), calpain inhibitor III (calpain inhibitor), and KN-62 (PX7R 
inhibitor) pretreatment attenuated TBI-induced BBB hyperpermeability in C57BL/6 mice. 
P2X7R knockout mice demonstrated reduced TBI-induced BBB hyperpermeability compared to 
the wild-type animals. 
In conclusion, ATP-sensitive P2X7R are involved in promoting BBB dysfunction and 
hyperpermeability via IL-1β-mediated activation of MMP-9/calpain pathways and subsequent 
disorganization of the TJs. Inhibition of this pathway can provide potential therapeutic targets 
against TBI-induced BBB hyperpermeability in vivo.
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CHAPTER I 
INTRODUCTION TO ENDOTHELIAL HYPERPERMEABILITY AND 
TRAUMATIC BRAIN INJURY* 
 
 
VASCULAR ENDOTHELIAL HYPERPERMEABILITY    
Vascular endothelial hyperpermeability is a significant clinical problem in 
conditions associated with traumatic and ischemic injuries, sepsis, atherosclerosis, 
acquired respiratory distress syndrome, diabetic retinopathy, thrombosis, inflammatory 
bowel disease and cancer [1; 2; 3]. Of those conditions, traumatic injuries are a public 
health problem in the USA, that accounts for 2.3 million admissions, 41 million 
emergency department visits annually and are also considered as a leading cause of 
death among the age group of 1 to 44 (http://www.nationaltraumainstitute.org/). One of 
the most common traumatic injuries is the traumatic brain injury (TBI). Traumatic brain 
injury is defined as any damage to the brain due to external forces like rapid 
acceleration/deceleration, blast waves, crush, or penetration by a projectile [4; 5; 6]. 
Disruption of the blood-brain barrier (BBB; the protective vascular barrier of the brain) 
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is the chief secondary injury that occurs following TBI and is often associated with 
microvascular hyperpermeability. Microvascular hyperpermeability can be defined as 
the leakage of fluid and proteins from the intravascular space into the extravascular 
space leading to tissue edema and multiple organ dysfunction [7]. Currently, there is no 
treatment to retard or halt the progression of secondary injuries that occur following TBI 
[8]. 
 
 
BLOOD-BRAIN BARRIER  
The brain is an extremely compact organ, tasked with performance and 
regulation of numerous activities, chief among these is maintenance of homeostasis in 
the body [9]. The delicate structure of the brain parenchyma renders it highly 
susceptible to injury, such as changes in forces and pressure [10] and consequently it is 
protected by a rigid skull. In addition to this macroscopic protection, the brain is also 
isolated from the blood or its fluid spaces on a microscopic level by three barrier layers: 
1) BBB formed by cerebrovascular endothelial cells [11; 12], 2) the epithelium of the 
choroid plexus, and 3) the arachnoid epithelium [13; 14]. Of these, the BBB 
demonstrates the greatest influence over the microenvironment of the brain and plays 
the largest role in promoting optimal neuronal function [15; 16]. 
Paul Ehlrich first described the BBB in the 1880s [17; 18]. During his 
investigations, he injected water-soluble dyes into the systemic circulation and noted 
that they did not enter the central nervous system (CNS). Later Edwin E. Goldman 
injected the same dyes into the cerebrospinal fluid (CSF) and demonstrated that they did  
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not pass into the systemic circulation [19; 20]. These discoveries paved the way for our 
current understanding of the BBB.  It is now known that the “barrier” identified by 
Ehlrich and Goldman is due to the complex interaction of the cerebral microvascular 
endothelial cells and the tight junctions between them [21]. The attachment of these 
endothelial cells forms a physical barrier. Additionally, the transport systems on the 
luminal and abluminal membranes regulate transcellular traffic and within the brain 
exhibit decreased endocytosis and transcytosis when compared to peripheral 
endothelium, thus forming a “transport barrier” [15].  Furthermore, the endothelial cells 
of the BBB are able to metabolize many toxic and neuroactive substances, functioning 
as a “metabolic barrier” [15].  Brain endothelial cells along with the other cells in the 
brain including astrocytes, pericytes, neurons and extracellular matrix (ECM) comprises 
the neurovascular unit (NVU) [22]. While the BBB is an essential and protective barrier 
of the brain its tightness is one of the limitations in transporting the therapeutic 
molecules across the BBB [23]. Efforts have been made to open the BBB transiently to 
permit the transit of various drug therapies following the breach in the BBB [23].  
 
 
Brain endothelial cells 
The vasculature of the brain is lined entirely with endothelial cells and these 
cells are normally the “front line defense” of the BBB. The integrity and permeability of 
the BBB is dictated mainly by tight junctions and adherens junctions between 
endothelial cells [22]. Tight junctions comprise integral transmembrane proteins 
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(claudins, occludin and junctional adhesion molecules) and accessory cytoplasmic 
membrane proteins (zonula occludens [ZO], cingulin and others) [24; 25] [28][29].  
In addition to these junctional proteins, endothelial cells also possess several 
other unique characteristics. Brain endothelial cells completely lack fenestrations, have 
high reflective coefficients and high electrical resistance [21; 23; 26; 27]. Brain 
endothelial cells have abundant mitochondria. This supports their numerous transport 
systems and high number of ionic channels, which regulate the contraction of vessels 
and activate signaling pathways. They also lack MHC class II molecules. Together these 
mechanisms allow restriction of leukocyte transmigration and ionic movement from 
blood into tissue [15; 27; 28], which is paramount in maintaining homeostasis in the 
brain.   
 
 
Tight junction proteins 
Tight junction proteins make up the structural and functional units of the BBB. 
Tight junctions are expressed as early as embryonic day 12, reflecting their importance 
in growth and development [29], and are normally composed of a variety of proteins, 
including claudins, occludin, zonula occludens, and tricellulin.  These proteins can be 
bicellular, like claudins or occludin, or they can be tricellular, as in tricellulin [30; 31]. 
Further, they encompass cytoplasmic proteins, like cingulin, afadin (AF6), 7H6, and 
zonula occludens (ZO)-1,-2, and -3 that bind the actin cytoskeleton within the cell [24; 
32; 33]. 
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Tight junctions regulate major functions of endothelial cells such as polarity, 
gene expression, signal transduction, differentiation, and undergo several post-
translational modifications in order to regulate these processes [34; 35; 36]. Tight 
junction proteins, because of their importance in regulation of the BBB, are clearly 
deranged with the fluid extravasation and swelling as seen after TBI but have also been 
shown to be involved in many pathological states including inflammatory bowel disease 
(IBD), cancers, and tumor metastasis [18].  
 
 
Zonula occludens  
Zonula occludens (ZO) proteins belong to the membrane associated guanylate 
kinases (MAGUK) family and are expressed as one of three major forms (ZO-1, -2, or -
3), all of which share sequence homology [37].  These proteins are multi-domain 
scaffolding cytoplasmic phosphoproteins, which link the transmembrane tight junction 
proteins like claudin to actin cytoskeleton via actin binding proteins cingulin and afadin.  
Domains at the C terminal are known to be, not only important for tight junction 
localization, but also in interaction with other tight junction proteins and 
immunoglobulins [33].  Zonula occludens proteins are important in regulating tight 
junction integrity, cell-cell interaction and adhesion, and signal transduction and, as 
such, are thought to possible play a large role in regulation of vascular permeability 
within the BBB, although this area is only beginning to be examined [18; 38]. Global 
gene knockout mouse model for ZO-1 have also been developed, however these animals 
exhibited lethal phenotype at embryonic day ten [39], further confirming its significance 
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in embryonic development. Unpublished data from our lab also demonstrate that ZO-1 
siRNA transfected monolayers but not claudin-5 or occludin siRNA transfected 
monolayers showed significant hyperpermeability (p<0.05). These studies further 
support the role of ZO-1 in maintaining the BBB tight junction integrity and 
permeability.   
 
 
TRAUMATIC BRAIN INJURY         
Traumatic brain injury (TBI) could be simply defined as any injury to the brain 
resulting from an external force.  Brain injuries are commonly sustained during motor 
vehicle accidents, sporting events, slips and falls, assaults, construction accidents, 
firearm mishaps and various military activities leading to a wide array of personality, 
cognitive, mental and emotional deficits [40]. Annually, it is estimated that around 10 
million people are affected by TBI worldwide, and of these, 5.3 million people are from 
the United States (US) [41]. According to the Centers for Disease Control and 
Prevention in 2012, the lifetime (the direct and indirect) costs of medical care and lost 
wages/productivity for patients with TBI are estimated to be $76.5 billion [42]. Two 
issues complicate examination of these numbers. First, many patients who suffer TBI 
are predisposed to development of other neurological diseases like seizures, epilepsy, 
dementia and Alzheimer‟s disease [7; 43]. It is unknown how many people diagnosed 
with neurodegenerative disorders actually are suffering from the sequela of head injury. 
Secondly, 75% of all TBIs are mild injuries, commonly referred to as concussions. 
Many of these patients never seek medical attention, and consequently the injuries go 
 7 
 
undiagnosed [4]. Therefore, the true cost and impact of TBI may be much higher than 
estimated.  Even so, we speculate by the year 2020, TBI will be one of the leading 
causes of death and disability worldwide.  
 
 
Traumatic brain injury and the blood-brain barrier  
Both traumatic and non-traumatic brain injury can precipitate BBB breakdown 
[44; 45; 46].  Derangements in the BBB have been studied both clinically and in the 
laboratory. They have been implicated in numerous pathologic states including cerebral 
ischemia, subarachnoid hemorrhage, concussive brain injury, meningitis, vascular 
dementia, CNS vasculitis, ischemic-reperfusion injury, epilepsy, seizures, cerebral 
malaria, neurologic inflammation, auto immune diseases like Alzhemier‟s, Parkinson‟s, 
multiple sclerosis, various cancers, acquired immune deficiency syndrome (AIDS), 
insulin resistance, obesity, stroke, infarction, and TBI.  Of these, TBI affects the most 
patients annually, and consequently warrants close and careful examination [23; 45; 46; 
47; 48].  
Traumatic brain injury has a very complex, dynamic and heterogeneous 
pathology, leading to a wide variety of injuries. Initially, direct tissue damage, known as 
the primary injury, occurs leading to immediate (usually in milliseconds to seconds), 
irreversible blood vessel and cellular damage.  Such injuries set into motion a cascade of 
events that can precipitate secondary injuries, a term referring to the perpetuation of 
damage either through host cellular response or by ongoing physiologic insults.  
Secondary injuries are multifactorial, often ranging from few hours to days after the 
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initial insult and, with proper treatment; they can be avoided, or reversed.   During the 
secondary phase, abnormalities in the BBB can be linked to several derangements that 
ultimately affect a patient‟s clinical course and, although BBB dysregulation is a highly 
transient and acute phenomenon, the secondary injuries that are triggered can be 
debilitating and can last a lifetime [49; 50]. The sequence of secondary events and 
clinical outcomes that occur following TBI are presented in Figure 1. Therefore, a better 
understanding of TBI, secondary injuries and the role of the BBB therein is paramount. 
Compromises in BBB permeability following brain injury may last from less than 4 
hours to up to 4 days, based on the molecular weight of the compounds [51].   
Several pathophysiologic stresses contribute to the breakdown of the BBB 
following TBI. Some of the significant secondary injury events in the brain include: 1) 
oxidative stress leading to free radical production and lipid peroxidation, 2) 
inflammation due to the release of various pro-inflammatory cytokines, nitric oxide and 
prostaglandins, 3) excitotoxicity occurring through NMDA receptor activation and 
calcium influx, 4) mitochondrial dysfunction occurring due to increase in Poly (ADP-
Ribose) Polymerase 1 (PARP-1) and calpains activation and decrease in NAD+/ATP 
levels, 5) apoptotic and necrotic cell death mechanisms, and 6) BBB disruption leading 
to cerebral edema, hypoxia and ischemic events [52]. Proteases, reactive oxygen species 
(ROS), angiogenic factors, pro-inflammatory cytokines, autoantibodies, leukocytes 
adhesion and migration, infection and pathogens can all contribute to BBB dysfunction, 
which includes hyperpermeability, loss of tight junction integrity and transporters, 
inadequate clearance of cell debris, detachment from other brain cells like pericytes, 
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astrocytes and interrupted basement membrane and activation of brain immune cells i.e. 
glial cells [53]. Activation of caspases, translocases and phopholipases not only trigger 
changes in membranes and DNA, but also cause cleavage of tight junctions and their 
reorganization [54]. Some of the substances released from neurons, connective tissue 
and blood cells include substance P, serotonin, histamine, and ATP, which can affect the 
BBB both on the blood and the brain side [15]. 
Neuroinflammation following TBI plays an important role in determining its 
pathophysiology. A few inflammatory molecules that increase in production following 
TBI, including interleukin-1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α), 
further worsen the pathologic insult by activating various matrix metalloproteinases 
(MMPs) [55; 56]. BBB dysfunction, if not addressed in a timely manner, can lead to 
neuronal dysfunction, neuroinflammation and neurodegeneration [53]. 
10 
Figure 1: Schematic of various events and clinical outcomes that occur following TBI.
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Models used in the study of TBI 
Although impressive strides have been published since 1900s, the current 
understating in TBI and the role of the BBB therein is far from complete and warrants 
continued investigation. A variety of models have been developed and employed for this 
task. In vitro models examine the response of brain tissue to different components of 
mechanical stimuli in real-time, including hydrostatic pressure, shear stress, stretch and 
strain, and compression. Morrison and co-workers explain these studies in detail in their 
review Morrison et al, 2011 [57]. In vitro models provides advantages such as 
repeatability, the ability to control conditions, and the ability to isolate variables to 
better understand specific facets of TBI, including the mechanisms that affect the BBB 
and how it responds to certain conditions [57; 58; 59]. However, promising, in vitro 
models thus far lack validation with in vivo models; as they do not fully represent the 
multiple dimensions and complex pathophysiology seen in an intact organism after 
injury [60]. 
Various in situ and in vivo imaging techniques were utilized to study the BBB at 
the molecular level after TBI, including fluid extravasation and leukocyte diapedesis 
through the BBB. However, at this time these techniques are not cost-effective and 
present many logistic hurdles [4]. 
Several in vivo models have been developed to examine TBI.  As with most scientific 
models, each exhibits strengths and weaknesses and in the study of TBI, these 
unfortunately are compounded by the heterogeneous nature of brain injuries. It is 
difficult to develop an in vivo model that mimics the diversity in patient age, gender, 
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baseline health, medication use, substance abuse, injury pattern and severity that are 
seen in actual TBIs [4; 32; 59; 61; 62]. With that said, invaluable insights into the 
pathophysiology of TBI have been gleaned utilizing animal models. The most 
commonly used models include: controlled cortical impact (CCI), fluid percussion 
injury (FPI), penetrating ballistic brain injury (PBBI) model, weight drop model, blast 
injury model, and acceleration head injury models [63]. Of them, CCI was the chosen 
model for this dissertation due to its various advantages as described in detail in the 
following section. 
Controlled cortical impact (CCI) 
This technique was developed first by Light Hall in 1988. It is widely used to study a 
range of neurological, cardiovascular, and histopathological variables. This is an 
invasive impact technique, widely used for studies in various animals. This technique 
uses a pneumatic or electromagnetic pump that drives the impactor onto the exposed 
dura. This technique is widely used to study cortical tissue loss, acute subdural 
hematoma, axonal injury, BBB dysfunction and coma [5]. This model is highly 
reproducible of many features of brain injuries like motor deficits, memory loss 
neuronal loss and also has the advantage of having lower mortality rate in animals [64; 
65; 66; 67]. Its drawback is the need for a craniotomy, which blurs its direct translation 
to human injury [5; 68; 69]. Blood-brain barrier opening in CCI model of TBI is 
biphasic in nature and maxed for the first time 4-6 hours after TBI, and then 3 days after 
[49]. Controlled cortical impactor has been shown to increase BBB permeability after 
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injury and interestingly, quantitative T1 magnetic resonance imaging techniques have 
shown that BBB disruption exacerbates with age following CCI [70]. Pictorial 
representation of the CCI instrument used in this dissertation is presented in Figure 2. 
Figure 2: Pictorial representation of the controlled cortical impact model of TBI. Above 
is the picture of Leica Benchmark stereotaxic impactor. In this technique, following 
craniotomy surgery, head of the mouse is positioned under the probe of a controlled 
cortical impactor on the stereotaxic frame as shown in the picture. Settings for velocity 
and dwell time can be adjusted using the velocity control knob and dwell time display. 
Depth of the probe into the brain cortex can be adjusted using the digital manipulator on 
the right side with a depth display.   
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IN VITRO AND IN VIVO METHODS TO ASSESS PERMEABILITY 
Permeability in the microvasculature works on the Starling principle, which 
illustrates the role of hydrostatic and oncotic pressures on the movement of fluid across 
capillary membranes. At the arteriolar end, hydrostatic pressure dominates the oncotic 
pressure, pushing the fluid into the extravascular space; while on the venular end, the 
oncotic pressure dominates the hydrostatic pressure, absorbing the proteins into the 
intravascular space. Thus, permeability is tightly regulated in the microvasculature. 
However, under pathological conditions, Lp, hydraulic conductivity which determines 
the permeability property of the capillary to water is increased leading to accumulation 
of large number of proteins into interstitial space producing an oncotic pressure that 
drives the flow into the extravascular space leading to edema. However, edema may 
also be affected by high capillary fluid pressure and increases in plasma proteins [71; 
72]. Many methods exist to measure permeability of fluid/solutes. Most of them aim to 
determine one of the several different factors of the capillary wall that determine 
permeability like the filtration coefficient (Kf), hydraulic conductivity (Lp), solute 
permeability coefficient (Ps), or the osmotic reflection coefficient (σ). 
Starling equation:  
Jv is the net fluid movement between compartments and [Pc – Pi] -  [πc –πi ] is the net 
driving force. Pc is the capillary hydrostatic pressure, Pi is the interstitial hydrostatic 
pressure, πc is the capillary oncotic pressure, πi is the interstitial oncotic pressure, Kf is 
the filtration coefficient (proportionality constant), and σ is the reflection coefficient. 
The most common in vitro technique used to study permeability is the membrane 
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permeability assay, while the most commonly studied in vivo method is Evans blue 
extravasation technique. Intravital microscopy (IVM) is an established technique that 
has gained a lot of popularity recently for measuring vascular permeability in animal 
models. 
In vitro techniques 
Quantitative measurements are more challenging to perform in the intact 
physiologically functional tissues. Hence, in vitro methods provide flexibility by 
employing cultured endothelial cell monolayers; enabling us to control various 
experimental conditions and allowing quantitative measurements. However, they also 
suffer from some limitations due to a chance for inadequate representations of real 
microvasculature. 
The artificial membrane permeability assay has become a very popular, versatile 
and extremely useful technique as an in vitro tool for measuring permeability across the 
membranes. In this design there is a polycarbonate/polystyrene filter separating the 
donor and the acceptor compartment. After growing the endothelial cells on the 
membrane (step 1 in figure 3), the test drug is usually added to the donor compartment 
and is allowed to diffuse through the polycarbonate membrane (step 2 in figure 3) [71; 
72]. At the end of the drug treatment study, fluorescent-tagged albumin or dextran of 
known molecular weight is added to the donor chamber and allow it to leak into 
acceptor chamber for 30 minutes (step 3 in figure 3). Fluorescence intensity is a 
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measure of FITC-dextran-10 kDa leakage into the lower chamber. Pictorial 
representation of an in vitro permeability assay is presented in Figure 3. 
Figure 3: Pictorial representation of in vitro permeability assay. This assay employs 
Transwell inserts (shown in blue color). Transwell insert consists of polycarbonate or 
polystyrene membrane (white color) that separates the upper/donor chamber (luminal) 
from the lower/acceptor chamber (alumina chamber; shown in gray color). In this 
procedure, brain endothelial cells (shown in yellow color) are initially grown as 
monolayers on Transwell inserts and brain endothelial cell complete medium (shown in 
pink color) is added both to donor as well as acceptor chamber as depicted in step 1. A 
test compound is added to the donor and acceptor chamber and allowed to act on the 
endothelial cell monolayers (step 2). Finally, in step 3, FITC-dextran-10 kDa is applied 
to the donor chamber and allowed to diffuse into the lower chamber for 30 minutes. 
Later, a small sample is collected from the lower chamber and measured 
fluorometrically at 485/535 nm (Excitation/Emission).  
FITC-dextran-10 kDa (5 mg/mL for 30 minutes) 
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In vivo techniques 
Intravital microscopy (IVM) and Evans blue dye (EBD) extravasation techniques are 
commonly used in vivo techniques to study BBB endothelial hyperpermeability. These 
techniques employ either dyes (e.g., Evans Blue) or fluorescently tagged albumin or 
dextrans of known molecular weight as markers of permeability. In vivo techniques 
work on the principle that brain is impermeable to leakage of intravascular dyes (e.g. 
Evans blue dye that binds to the serum albumins) or fluorescent-tagged albumin or 
dextrans into the extravascular space; due to the high molecular weight of the dye-
albumin complex or fluorescently tagged albumin or dextrans. However, when the BBB 
integrity is compromised, the dye-albumin complex or fluorescently tagged 
albumins/dextrans leak into the extravascular space of the brain and the extent of 
leakage into the extravascular space is a direct indication of vascular permeability as 
demonstrated in Figure 4. 
 18 
 
 
 
 
 
 
 
 
Figure 4: Principle of in vivo permeability studies. Under normal conditions, brain 
endothelial cell lining (pink color boxes) separates the blood from the extravascular 
space, preventing any leakage of dye/fluorescently tagged molecules from passing 
through the BBB (A); however, following brain trauma an increase in endothelial 
permeability results in leakage of plasma and proteins into the extravascular space of the 
brain (B). The extent of permeability can be determined as a ratio of extravascular to 
intravascular leakage or by comparing the total dye leakage into brain tissue compared 
to a control animal.   
 
 
Intravital microscopy imaging 
Wagner first described intravital microscopy (IVM) in the 19
th
 century, which 
has evolved considerably by the advent of modern microscopy and imaging techniques. 
It is a powerful visualization technique used to study the vascular changes in live 
A B 
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animals. Pictorial representation of an intravital microscope is shown in the Figure 5. In 
this technique, fluorescein isothiocyanate (FITC) labeled dextran is injected 
intravenously into the animal and its leakage into the brain tissue over a period is 
monitored. In this procedure, mice are anesthetized with urethane, i.p. injection (2 
mL/kg body weight) followed by FITC-dextran-10 kDa, i.v. injection (50 mg/mL; 100 
μL) via the tail vein. FITC-dextran is injected into the animal five minutes prior to sham 
surgery (only craniotomy) or traumatic brain injury using a controlled cortical impactor. 
The craniotomy process involves making a circular window on the chosen (in this case, 
right hemisphere) hemisphere of the brain between bregma and lambda on the skull of 
the animal using a microdrill. The surgical site is cleaned and a cover glass is placed 
over the surgical site followed by sealing it with super glue. The animal is then placed 
under the microscope and the images were captured at 30, 50, and 70 minutes using 
Leica 40X N2 objective. Typically, vessels ranging from 20-40 μm were chosen for 
imaging pial microcirculation using FITC imaging cube with emission wavelength of 
525 nm. Y-axis represents the ratio of FITC-fluorescence intensity values extravascular 
to intravascular space normalized to FITC-fluorescence intensity values obtained at 30 
minutes baseline. 
Pictorial and graphical representation of IVM images obtained from animals 
subjected to sham and mild TBI (2 millimeter depth; 0.5 meters/second velocity and 100 
milliseconds contact time) injury over a period of 30, 50 and 70 minutes are presented 
in the figure 6A and B. 
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Figure 5: Pictorial representation of the intravital microscopy technique. This technique 
is employed to study the extent of vascular leakage of fluorescein isothiocyanate (FITC) 
dextran into the extravascular space. Animals will be placed on a warming pad on the 
microscope stage and imaged using a 40X water immersion objective over a period of 
time. Images will be collected using the computer and analyzed using NIS-Elements-
Nikon imaging software.   
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Figure 6: Effect of TBI on FITC-dextran leakage in mouse pial microvasculature. In 
this procedure, animals were subjected to sham injury (only craniotomy; n=5) or mild 
TBI injury (n=5). Pictorial representation of mice subjected to sham vs. mild TBI over a 
period of 30, 50, and 70 minutes (figure A).  
Quantitative analysis further confirmed that animals subjected to TBI demonstrated 
more leakage of FITC-dextran-10 kDa into the extravascular space (figure B). Y-axis 
represents ratio of FITC-dextran fluorescence intensity outside of the vessel to inside 
(figure B). Data shown here are represented as mean ± SEM; p≤ 0.05. „*a‟ indicates 
significant increase compared to the sham group. Statistical significance was determined 
by two-way ANOVA followed by Tukey post-hoc test.  
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Evans blue extravasation study 
Evans blue is an alkaline dye that binds to albumin in the blood. It is a popular 
dye used to study vascular permeability in various physiological disorders. In this 
procedure, the animals are anesthesized with urethane, i.p. injection (2 mL/kg body 
weight). Head is shaven and lubricating eye ointment is appplied to the eyes. Animals 
are then injected with Evans blue (2% wt/vol in saline, 4mL/Kg body weight) via the 
tail vein and allowed to circulate for 30 minutes, following which the animals were 
subjected to either sham (only craniotomy) or TBI (craniotomy followed by CCI-TBI 
injury). Settings for mild TBI injury included: 1 millimeter depth of injury, 5 
meters/second velocity and 300 milliseconds contact time, while that for moderate TBI 
included: 2 millimeters depth of injury, 5 meters/second velocity and 300 milliseconds 
contact time. These settings were chosen for our preliminary studies in order to confirm 
that TBI induces BBB hyperpermeability in vivo. However, based on a thorough 
literature review, different settings were used for further chapters and the corresponding 
results are described in the various chapters. Drug treatments to be studied, can be 
administered along with Evans blue as pretreatment prior to sham or TBI. Pictorial 
representation of animals prior to and following Evans blue injection are shown in the 
Figure 7A and B. Figure 7C presents the pictures of Evans blue-injected mice following 
sham injury and TBI injury . 
One hour post-TBI, mice were transcardially perfused with ice-cold saline for 
atleast 20 minutes and brains were extracted. Ipsilateral brain cortices were carefully 
isolated and homogenized in 1 mL of 50% (wt/vol) trichloroacetic acid (TCA) in saline. 
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The resulting samples were then centrifuged at 6000g for 20 minutes at 4 C. 
Supernatants extracted were then diluted in 3 parts of 95% ethanol and measured 
fluorometrically at 620/680nm (Excitation/Emission). Evans blue concentrations in the 
samples were then evaluated using external standards of Evans blue ranging from 0-
5000 ng/mL, prepared in the same solvent (1:3; TCA: 95% ethanol). Evans blue amount 
in the samples was expressed as ng/brain cortex ± SEM. Statistical differences among 
groups were determined by one-way analysis of variance (ANOVA) followed by 
Bonferroni post hoc test to determine significant differences between specific groups. A 
value of p<0.05 was considered statistically significant. Quantitative analysis of TBI-
induced Evans blue leakage in mice is shown in Figure 8.  
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Figure 7: Pictorial representation of Evans blue-injected mice following sham injury 
and TBI. Figure A shows the dorsal side of the animal head prior to (left) and after 
Evans blue injection. Figure B shows the ventral side of the animal prior to (left) and 
after Evans blue injection (right). Evans blue binds to the albumin in the blood. Tail 
vain injection of Evans blue turns the blood blue by dyeing the entire systemic 
circulation. C shows animal with craniotomy surgery only i.e. sham (left) and after TBI 
(right).  
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Figure 8: Effect of TBI on Evans blue leakage in mouse brain cortex. Animals were 
grouped into sham injury (n=4), mild TBI injury (n=5) and moderate TBI injury (n=5). 
Data are represented as ng/brain cortex ± SEM; p≤ 0.05. „*a‟ indicates significant 
increase compared to the sham group.    
The graph on the right hand corner shows a standard curve for Evans blue 
concentrations ranging from 0 to 5000 ng/mL prepared in TCA: ethanol (1:3);  plotted 
on X-axis. Y-axis represents relative fluorescence units (RFU), measured at 620/680 
nm.  
 
 
 
 
 
 
0
400
800
1200
E
v
a
n
s 
B
lu
e 
L
ea
k
a
g
e 
 
*a 
*a 
y = 0.2403x + 22.493 
R² = 0.9935 
0
500
1000
1500
0 2000 4000 6000
R
F
U
 
Concentrations 
26 
CONCLUSION 
Blood-brain barrier (BBB) dysfunction and its contribution towards various 
diseases have been identified and explained in detail by Obermeier et al, 2013 [53]. 
Optimal functioning of BBB is essential for neuronal activity and normal brain 
functioning. A better understanding of the complex mechanisms involved in TBI-
induced BBB dysfunction will lead to identification of potential drug targets. As tight 
junctions govern much of the function of the BBB and thus are paramount in mediating 
the vascular permeability changes in the BBB seen after TBI, focus on these proteins as 
therapeutic targets may be of benefit.  Understanding the roles of tight junction proteins 
and the manner in which they are targeted by various proteases after TBI may assist in 
understanding BBB hyperpermeability, edema and the associated elevation of 
intracranial pressure (ICP) after TBI and may even provide therapeutic targets to 
combat this process. Knowledge of the interplay between the various components of the 
BBB and the molecular pathways that regulate them is critical and a more thorough 
understanding of the mechanisms that govern these interactions is important.  
Conditional knockouts of specific components of BBB or various molecular mediators 
can provide a deeper understanding of the functionality of the molecular players and our 
lab is currently moving towards that direction.  
A multitude of medical and scientific advancements have been made in the field 
of trauma and brain research since the 1900s. Studies that focus on the basic 
mechanisms of brain injury and BBB dysfunction are beginning to emerge and may 
shed light on potential new therapeutic interventions. Although understanding the 
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pathophysiology of the BBB is intricate and extremely complex, the mechanisms 
involved in its breakdown in TBI require further study and hold great promise for 
treatment options for brain injury.   
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CHAPTER II 
MATRIX METALLOPROTEINASE-9-MEDIATED MECHANISMS IN 
REGULATING BLOOD-BRAIN BARRIER DYSFUNCTION AND 
HYPERPERMEABILITY 
SUMMARY 
Microvascular hyperpermeability is the excessive leakage of fluid and proteins 
from the intravascular space into the interstitium. Hyperpermeability that occurs at the 
level of the blood-brain barrier (BBB) often leads to vasogenic brain edema following 
traumatic and ischemic brain injuries. At the cellular level, the tight junction proteins 
(TJPs) regulate the properties of the BBB. Zonula occludens-1 (ZO-1) is an important 
TJP that binds to the transmembrane TJPs and actin cytoskeleton intracellularly. The 
pro-inflammatory cytokine, interleukin-1 beta (IL-1β) activates downstream signaling 
pathways as well as various proteolytic enzymes. Matrix metalloproteinases (MMPs) 
play an important role in promoting secondary injuries following trauma/ischemia. 
Recent studies demonstrate melatonin, a pineal hormone, as a potential inhibitor of 
MMP-9. We hypothesized that melatonin pretreatment provides protection against IL-
1β treatment-induced BBB dysfunction and hyperpermeability in vitro and following 
traumatic brain injury (TBI) in vivo. 
Rat brain microvascular endothelial cells (RBMECs) were used for in vitro 
studies. RBMEC monolayers were grown on Transwell inserts and the cells were 
pretreated with GM6001 (broad-spectrum MMP inhibitor), MMP-9 inhibitor-1 (MMP-9 
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specific inhibitor), melatonin or transfected with MMP-9 siRNA followed by treatment 
with IL-1β. Tight junction integrity and cytoskeletal assembly were assessed by ZO-1 
immunofluorescence and rhodamine phalloidin labeling for f-actin respectively. Protein 
and mRNA expression of ZO-1 was evaluated by Western blotting and RT-PCR 
techniques respectively. Cell viability and MMP-9 activity were assessed 
fluorometrically. Effect of melatonin pretreatment on TBI-induced BBB 
hyperpermeability in a mouse model was evaluated fluorometrically by Evans blue 
extravasation assay. 
The results from our study demonstrate that acute IL-1β treatment-induced BBB 
hyperpermeability was significantly attenuated on pretreatment with GM6001, MMP-9 
inhibitor-1, melatonin or MMP-9 siRNA transfection in vitro. Melatonin and MMP-9 
inhibitor-1 pretreatment attenuated IL-1β-induced MMP-9 activity, loss of ZO-1 
junctional integrity and f-actin stress fiber formation. IL-1β treatment affected neither 
ZO-1 protein or mRNA expression nor cell viability. Melatonin pretreatment attenuated 
TBI-induced BBB hyperpermeability in vivo. 
These results demonstrate that MMP-9-mediated mechanisms play an important 
role in regulating IL-1β-induced BBB dysfunction and hyperpermeability. Melatonin 
treatment can be a potential strategy in attenuating TBI-induced BBB hyperpermeability 
in a mouse model of TBI. 
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INTRODUCTION 
Microvascular hyperpermeability is the abnormal extravasation of plasma 
proteins and fluid into extravascular space leading to vasogenic edema. 
Hyperpermeability in the brain occurs at the level of blood-brain barrier (BBB). The 
BBB is a semipermeable membrane that separates the systemic circulation from the 
brain parenchyma. Optimal functioning of the BBB is crucial for maintaining the 
homeostasis of the brain. The key structural and functional elements in maintaining the 
integrity of the BBB are the tight junctions [63]. Tight junctions primarily include 
transmembrane (occludin, claudins, junctional adhesion molecules) and membrane 
bound tight junctions (zonula occludens [ZO]). Zonula occludens-1 (ZO-1) acts as a 
scaffolding molecule mediating the link between the transmembrane tight junctions and 
the actin cytoskeleton [63]. It plays an important role in maintaining the important 
properties of the BBB including resistance and permeability [63]. Alterations in BBB 
integrity leading to hyperpermeability and vasogenic edema often occur following 
inflammation [73; 74].  
A variety of pro-inflammatory molecules are activated following various 
vascular disorders associated with traumatic brain injury (TBI), ischemia, cerebral 
infections, stroke, brain diseases, etc [75; 76]; leading to various ill-pathologies like 
microvascular leakage, brain edema leading to swelling, neuronal injury and death [74; 
77]. Interleukin-1 beta (IL-1β) plays a central role in mediating the process of 
neuroinflammation [78]. It is a well-established pro-inflammatory cytokine known to 
induce BBB hyperpermeability in endothelial cell monolayers [74; 76; 79; 80]. It also 
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plays an important role in TBI pathophysiology [76]. Interleukin-1β levels and matrix 
metalloproteinase-9 (MMP-9) activity increase in brain following TBI; also, the role of 
MMP-9 in BBB tight junction disruption is also well studied [81; 82; 83]. Studies done 
by Wu et al, 2010 in intracerebral hemorrhagic (ICH) models suggest that IL-1β may be 
a key mediator molecule in MMP-9 activation and subsequent ZO-1 disruption [84]. So 
far, there are no evidences that confirm the direct contribution of MMP-9 in mediating 
IL-1β-induced BBB hyperpermeability, although other pro-inflammatory molecules like 
tumor necrosis factor-alpha (TNF-α) are shown to induce MMP-9 activity and 
endothelial hyperpermeability [85]. Hence, we hypothesized that IL-1β treatment-
induced BBB hyperpermeability may occur via MMP-9-mediated mechanisms. 
Our studies further explored the role of melatonin as a potential MMP-9 
inhibitor apart from being a pineal hormone with anti-inflammatory and anti-oxidant 
properties. Recent studies by Rudra et al, 2013 indicate that melatonin inhibits MMP-9 
by binding to its active catalytic site [86]. Anti-MMP-9 properties of melatonin 
following burn injury-induced endothelial hyperpermeability are also explored [87]. 
However,  role of melatonin in attenuating IL-1β-induced BBB hyperpermeability is yet
unknown. Furthermore, we  employed melatonin to study its effect in mouse model of
TBI. This study aims to address the following questions: 
 What is the effect of acute IL-1β treatment on BBB endothelial cell permeability in
vitro? 
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 What is the effect of melatonin and MMP-9 specific inhibitors on IL-1β treatment-
induced BBB hyperpermeability, loss of tight junctional integrity, changes in actin 
cytoskeletal assembly and MMP-9 activity? 
 What is the effect of IL-1β treatment on total number of viable cells and ZO-1
protein and mRNA expression in vitro? 
 Can melatonin be used as a protective therapeutic agent against TBI-induced BBB
hyperpermeability in vivo? 
MATERIALS AND METHODS 
Materials 
Rat Brain Microvascular Endothelial Cells (RBMECs) and RBMEC Medium 
were obtained from Cell Applications Inc. (San Diego, CA). SensoLyte® 520 MMP-9 
fluorometric Assay Kit was purchased from Anaspec Inc. (San Jose, CA). Transwell® 
24-well plates were obtained from Corning Costar (New York, USA). Nunc Lab Tek II-
CC, 8-well glass chamber slides, Interleukin-1β human, melatonin, fibronectin from 
bovine plasma, β-actin, albumin from bovine serum, Evans blue, trichloroacetic acid 
and fluorescein isothiocyanate-dextran-10 kDa were purchased from Sigma Aldrich (St. 
Louis, MO). Rabbit anti ZO-1 (Cat # 617300), mouse anti ZO-1 (Cat # 339100),  0.25% 
Trypsin (1X), Opti-MEM (1X)/reduced serum medium, Dulbecco's modified Eagle‟s 
medium (DMEM; with high glucose, HEPES, no phenol red (1X)), NuPAGE Novex® 
10% Bis-Tris protein gels, NuPAGE® MOPS SDS Running Buffer, NuPAGE® 
Transfer Buffer, HyClone Dulbecco's phosphate buffered saline (PBS, without calcium, 
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magnesium, or phenol red), TRIzol® Reagent, SuperScript® IV First-Strand Synthesis 
System, Halt® Protease Inhibitor Cocktail (100X), Pierce™ ECL Western Blotting 
substrate and rhodamine phalloidin were purchased from Thermo Fisher Scientific 
(Carlsbad, CA). Goat anti-mouse IgG-HRP and donkey anti-rabbit IgG-FITC secondary 
antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). 
EZViable™ Calcein AM Cell Viability fluorometric assay kit was bought from 
Biovision (Milpitas, CA). We also purchased Vector VECTASHIELD® Mounting 
Media with DAPI from Vector Laboratories (Burlingame, CA). Pierce™ BCA Protein 
Assay Kit and RT² qPCR Primer Assay for Mouse GAPDH were purchased from 
Qiagen (Valencia, CA). GM6001 (also called as Ilomastat or Galardin) and MMP-9 
inhibitor 1 were purchased from Calbiochem (Billerica, MA). Cell Lysis Buffer (10X) 
was bought from Cell Signaling Technology, Inc. (Danvers, MA). Primers were 
purchased from Thermo Fisher Scientific (Carlsbad, CA). MMP-9 siRNA and control 
siRNA (ON-TARGETplus siRNA) were purchased from Dharmacon, General Electric 
(Pittsburgh, PA). 
In vitro BBB model 
Primary cultures of RBMECs derived from the brain of adult Sprague Dawley 
rat were purchased from the Cell Applications Inc. (San Diego, CA). RBMECs were 
initially grown on 0.05% fibronectin-coated cell culture dishes, using the RBMEC 
medium in a cell culture incubator (95% O2, 5% CO2 at 37 °C). Endothelial cells were 
treated with 0.25% trypsin-EDTA for cell detachment. Detached cells were then grown 
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on fibronectin-coated Transwell® inserts, chamber slides or 100 mm dishes for 
experimental purposes. RBMEC passages 8-10 were chosen for all the experiments.  
 
 
Animals and surgeries 
C57BL/6 mice (25-30 g) were purchased from Charles River Laboratories 
(Wilmington, MA). Animals were maintained at the Texas A&M University Health 
Science Center College of Medicine and Baylor Scott and White Health animal facility 
on a 12:12 hour dark/light cycle, with free access to food and water. The room 
temperature was maintained at 25° ± 2 °C. Surgical and experimental procedures used 
in this study were conducted after approval by the Institutional Animal Care and Use 
Committee. The facility is approved by the Association for Assessment and 
Accreditation of Laboratory Animal Care International in accordance with the National 
Institutes of Health guidelines. 
 
 
Craniotomy procedure 
 The head of the animal was shaven and the surgical site on the surface of the 
head was cleaned with an alcohol wipe. Lubricating ointment was applied to the eyes. 
Midline incision on the scalp helps to remove the skin from top of the skull exposing the 
sagittal suture, bregma and lambda. A circular craniotomy window, 3-4 mm in diameter 
was made on ipsilateral hemisphere, between lambda and bregma using a microdrill. 
The resulting bone flap was removed. Sham animals received only craniotomy surgery, 
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while TBI injury group receives brain injury via controlled cortical impactor following 
craniotomy procedure.  
 
 
Controlled cortical impactor 
These studies employ Benchmark™ Stereotaxic Impactor from Leica, for 
inflicting traumatic brain injury in mice. Following craniotomy procedure, the animals 
were mounted on the stereotaxic frame. An impactor probe of 3 mm diameter was used 
to impact the exposed part of the brain. The depth of the injury was used to determine 
the severity of the injury. Settings for mild TBI used in this study are: 2 millimeters 
depth, 0.5 meters/second velocity and 100 milliseconds contact time as described in 
Chen et al, 2014 [88]. 
 
 
Treatments 
Melatonin at a dose of 10 mg/kg was used for the acute drug administration 
studies. This dose was chosen based on the studies done in mouse model of TBI [89]. 
Melatonin was administered via the tail vein along with Evans blue injection and 
allowed to circulate for 30 minutes prior to TBI.  
 
 
Monolayer permeability assays 
RBMECs were grown on fibronectin-coated Transwell® inserts as monolayers 
for 72-96 hours and regularly checked for confluency. Monolayers were initially 
exposed to phenol red free DMEM for 45 minutes to an hour. DMEM treated cells were 
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then treated with various concentrations of IL-1β (1-100 ng/mL) for 2 hours or IL-1β 
(10 ng/mL) treatment at various time points (1-4 hours). At the end of the treatment, 
FITC labeled dextran-10 kDa (5 mg/mL; 30 minutes) was applied to the luminal 
compartment. One hundred microliters of sample was collected from the abluminal 
compartment at the end of 30 minutes and measured fluorometrically at 485 nm/520 nm 
(Excitation/Emission) using Fluoroskan Ascent™ FL Microplate Fluorometer and 
Luminometer (Vantaa, Finland). These studies provided information on the minimal 
dose and time exposure of IL-1β to induce BBB endothelial cell hyperpermeability.  
Using the above information, a separate set of experiments were conducted to 
study the effect of GM6001 (10 μM; 1 hour), MMP-9 inhibitor 1 (5 nM; 1 hour) and 
melatonin (10 μg/mL; 1 hour) pretreatment on IL-1β (10 ng/mL; 2 hours) treatment-
induced monolayer hyperpermeability. At the end of the experiment, FITC-dextran-10 
kDa was added to the donor chamber and fluorescence intensity measurements were 
performed as described above.   
Melatonin dose and time exposure were chosen from the studies done in our lab 
in burn trauma models [87]. MMP-9 inhibitor 1 used in these studies is a cell-
permeable, potent, selective and reversible MMP-9 inhibitor with IC50 at 5nM for MMP-
9 inhibition. It inhibits other MMPs at concentrations higher or lower than 5nM, hence 
5nM was specifically chosen for these studies. MMP-9 inhibitor 1 concentrations were 
chosen from the studies done in our lab to study the effect of TNF-α-induced BBB 
hyperpermeability [85]. The dose and exposure time for GM6001 were obtained from 
Simaro et al, 2012 [90].  
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Untreated cells served as control. Each experiment was repeated four times. 
Fluorescence intensity values were plotted on the Y-axis and represented as % control. 
Data were expressed as mean ± % SEM and statistical differences among groups were 
determined by one-way analysis of variance (ANOVA) followed by Bonferroni post hoc 
test to determine significant differences between specific groups. A value of p<0.05 was 
considered statistically significant. 
 
 
MMP-9 knockdown studies  
RBMECs were grown on fibronectin-coated Transwell® inserts for 24 hours and 
treated with control siRNA or MMP-9 siRNA at a concentration of 25 nM for 48 hours. 
Transfection was performed according to manufacturer‟s instructions. Transfected 
monolayers were then exposed to IL-1β (10 ng/mL; 2 hours) and permeability was 
determined based on the leakage of FITC-dextran-10 kDa (5 mg/mL; 30 minutes) 
leakage from the luminal to the abluminal chamber. One hundred microliters of the 
sample was obtained from the abluminal chamber and fluorescence intensity was 
measured at 485/520 nm (Excitation/Emission) using Fluoroskan Ascent™ FL 
Microplate Fluorometer and Luminometer. 
Untreated cells were used as control. Each experiment was repeated four times. 
Fluorescence intensity was plotted on the Y-axis and represented as % control. Data 
were expressed as mean ± % SEM and statistical differences among groups were 
determined by one-way analysis of variance (ANOVA) followed by Bonferroni post hoc 
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test to determine significant differences between specific groups. A value of p<0.05 was 
considered statistically significant. 
Measurement of MMP-9 activity 
A SensoLyte® 520 MMP-9 fluorometric Assay Kit was employed to measure 
the MMP-9 activity in the cells. This kit detects the MMP-9 activity in samples by using 
a 5- carboxyfluorescein  Ser - Leu - Gly - Arg - Lys - Ile - Gln - Ile - Gln - 
Lys(QXL
®
520) - NH2  (5-FAM/QXL™ 520 fluorescence resonance energy transfer
(FRET) peptide). In intact FRET peptide, the fluorescence of 5-FAM is quenched by the 
QXL™ 520. However, on cleavage of the peptide by MMP-9 fluorescence is recovered 
and measured at 490/520 nm (Excitation/Emission). 
In this procedure, RBMECs were grown in petri dishes until confluency is 
achieved. Cells were then pretreated with MMP-9 inhibitor 1 (5 nM; 1 hour) or 
melatonin (10 μg/mL; 1 hour) followed by IL-1β (10 ng/mL; 2 hours). At the end of the 
experiment, cells were washed twice in PBS and exposed to the assay buffer provided in 
the kit. Cells were then scraped and the cell lysates were collected. Cell lysates were 
briefly sonicated and centrifuged in order to collect supernatants. Supernatants were 
used to measure the MMP-9 activity in the cells. Equal amounts of proteins were taken 
in each well and 4-aminophenylmercuric acetate (APMA) was added to samples and 
incubated for 2 hours in dark; in order to activate the pro-MMPs. To the activated 
samples, MMP-9 substrate, 5-FAM/QXL 520 FRET peptide was added and incubated 
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for another 30 minutes in dark and read fluorometrically at 490/520 nm 
(Excitation/Emission). 
Untreated cells served as control. Each experiment was repeated four times. 
MMP-9 activity was expressed as relative fluorescence units (RFU) and plotted on the 
Y-axis. Data were expressed as mean ± SEM and statistical differences among groups 
were determined by one-way analysis of variance (ANOVA) followed by Bonferroni 
post hoc test to determine significant differences between specific groups. A value of 
p<0.05 was considered statistically significant. 
ZO-1 immunofluorescence and rhodamine phalloidin labeling for f-actin 
Zonula occludens-1 junctional localization and f-actin stress fibers were 
assessed. RBMECs were grown on chamber slides for overnight. Cells were initially 
exposed to Opti-MEM/reduced serum medium, followed by pretreatment with 
melatonin (10 μg/mL; 1 hour) and MMP-9 inhibitor 1 (5 nM; 1 hour) and subsequently 
IL-1β (10 ng/mL; 2 hours) treatment. Cells were then fixed in 4% paraformaldehyde in 
PBS for 10-15 minutes and permeabilized in 0.5% Triton-X 100 in PBS for another 10-
15 minutes. Cells were blocked using 2% bovine serum albumin (BSA) in PBS for an 
hour at room temperature. Cells were then incubated overnight in anti-rabbit primary 
antibodies against ZO-1 (#617300; 1:150) in 2% BSA-PBS, followed by incubation 
with anti-rabbit IgG-FITC conjugated secondary antibody for an hour at room 
temperature. Cells were then washed and mounted using VECTASHEILD® Antifade 
Mounting Media with DAPI for nuclear staining. 
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Following treatment study, cells were fixed, permeabilized, and blocked in 2% 
BSA-PBS as described earlier. Cells were then labeled with rhodamine phalloidin (1:50) 
in 2% BSA-PBS for 20 minutes. Chamber slides were then washed and mounted using 
VECTASHIELD® Antifade Mounting Media with DAPI for nuclear staining. 
Cells were visualized and scanned at a single optical plane with an Olympus 
Fluoview 300 Confocal Microscope (Center Valley, PA), with a PLA PO 60X water 
immersion objective. Untreated cells served as control. Each experiment was repeated 
four times. 
Real time-PCR studies 
RBMECs were grown on 100 mm cell culture dishes until 80-90% confluency 
was reached. Cells were then pretreated with melatonin (10 μg/mL; 1 hour) and MMP-9 
inhibitor 1 (five nM; 1 hour) followed by IL-1β (10 ng/mL; 2 hours). Following 
treatments, cells were washed thrice in PBS and total RNA was then extracted using 
TRIzol® reagent according to the manufacturer‟s instructions. RNA concentration and 
quality were determined by employing the ratio of absorbance at 260/280 nm using 
Biotek Synergy Hybrid Spectrophotometer (Winooski, VT).  Reverse transcription was 
performed using the SuperScript® IV First-Strand Synthesis System. Quantitative real 
time PCR was performed using the RT² SYBR Green Fluor qPCR Mastermix with the 
following primer pairs for ZO-1: Forward primer: 5′-
CCTCTGATCATTCCACACAGTC-3′, Reverse primer: 5′-
TAGACATGCGCTCTTCCTCTCT-3′, MMP-9: Forward primer: 5'-
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GGCTAGGCTCAGAGGTAA-3', Reverse primer: 5'-GACGTTGTGTGAGTTCCAG-
3' and GAPDH: Forward primer: 5′-AATGTATCCGTTGTGGATCT-3′, Reverse 
primer: 5′-CAAGAAGGTGGTGAAGCAGG-3′ were used. Real-time PCR detection 
was carried out using Stratagene Mx3000P qPCR System, Agilent Technologies (La 
Jolla, CA), using 1 μL of cDNA for 10 minutes at 95°C, followed by 40 cycles of 15 sec 
at 95°C for denaturation and 1 min at 60°C for annealing. Relative abundances of target 
genes were calculated by normalizing Ct values to endogenous control glyceraldehyde 
3-phosphate dehydrogenase (GAPDH).  
Cells were treated with IL-1β, while untreated cells served as control. Each 
experiment was repeated three times. Relative gene expression of ZO-1 was obtained by 
normalizing the Ct values to the endogenous control GAPDH for each repeat. 
Normalized Ct values were expressed as mean ± SEM. Statistical differences among 
groups were determined by one-way analysis of variance (ANOVA) followed by 
Bonferroni post hoc test to determine significant differences between specific groups. A 
value of p<0.05 was considered statistically significant. 
 
 
Western blot analysis 
Western blot analysis was performed to investigate the expression of ZO-1 
protein in RBMECs. Cells were initially exposed to reduced serum medium followed by 
IL-1β (10 ng/mL; 2 hours) treatment. At the end of the study, cells were washed twice 
in ice-cold PBS and incubated in ice-cold cell lysis buffer (1X) along with protease 
inhibitor cocktail (1X) for 5 minutes in cell culture dishes. Cells were then scraped, 
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sonicated and centrifuged at 14,000g for 10 minutes at 4C. Supernatant was collected 
from the extracts and protein concentration was determined using protein assay kit. 
Equal amounts of total protein (50 μg) were separated by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) on 10% Bis-Tris precast gels at 
constant voltage (145 V) for 180 minutes. Proteins were then transferred onto the 
nitrocellulose membrane at constant voltage (30 V) for overnight and the membranes 
were blocked using 5% nonfat dry milk in Tris-Buffered Saline (TBS) with 0.05% 
Tween-20 for 3 hours and subsequently incubated with primary mouse monoclonal anti 
ZO-1 antibody (1:250 dilution). Membranes were washed thrice in TBS-T and 
incubated with the goat anti-mouse IgG-HRP conjugated secondary antibody. After 
washing, the immunoblots were visualized by ECL Western Blotting Substrate. 
Untreated cells served as control. Equal amount of protein sample loading was verified 
by assessing β-actin protein expression. Each experiment was repeated four times. 
Cell viability studies 
An EZViable™ Calcein AM Cell Viability Assay Kit (Fluorometric) was used 
for quantify the number of viable cells. Calcein AM is a non-fluorescent, hydrophobic 
compound that easily penetrates intact and live cells. Hydrolysis of the calcein AM by 
intracellular esterase produces a hydrophilic, strongly fluorescent compound that is 
retained in the cell cytoplasm, which can be measured at 485/530 nm 
(Excitation/Emission). 
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Equal numbers of cells were grown on sterile black 96 well trays. On reaching 
confluency, growth media is discarded and cells were washed in PBS and pre-exposed 
to phenol red-free medium for 1 hour. Cells were divided into control (untreated) and 
IL-1β (10 ng/mL) treatment groups. Following treatments, cells were then exposed to 
calcein buffer solution (calcein AM: calcein dilution buffer in 1:500 dilution) and 
incubated at 37C for 30 minutes and a fluorometric reading was obtained.  
Fluorescence intensity was plotted on the Y-axis and represented as % control. 
Data were expressed as mean ± % SEM and statistical differences among groups were 
determined by one-way analysis of variance (ANOVA) followed by Bonferroni post hoc 
test to determine significant differences between specific groups. A value of p<0.05 was 
considered statistically significant. 
 
 
Evans blue leakage studies  
Evans blue dye binds to the albumin in the blood enabling us to detect the 
vascular leakage into the extravascular tissue following traumatic brain injury. C57BL/6 
mice (25-30 g) were anesthetized with urethane, i.p. injection (2 mL/kg body weight) 
followed by Evans blue dye, i.v. injection (2% wt/vol in saline; 4 mL/kg body weight). 
Evans blue was allowed to circulate in the animal for 30 minutes prior to performing 
sham surgery (only craniotomy) or TBI using controlled cortical impactor. Drugs were 
given to the animal along with Evans blue injection and allowed to circulate for 30 
minutes as well. 75% ethanol was used a vehicle control. Settings for mild TBI are 
described in the CCI procedure.  
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Animals were grouped into Sham (only craniotomy; n=6), Vehicle + Sham (75% 
ethanol injection followed by craniotomy; n=6), Vehicle + TBI group (75% ethanol 
followed by mild TBI; n=5), and melatonin +TBI group (melatonin [10 μg/gram body 
weight of the animal] injection followed by mild TBI; n=6). 
One-hour post-TBI, animals were transcardially perfused with sterile saline 
containing heparin (1000 U/mL) for at least 20 minutes. Brains were extracted and brain 
cortex was carefully separated and weighed. Brain cortices were then homogenized in 1 
mL of 50% (wt/vol) trichloroacetic acid (TCA) in saline. Homogenate was then 
centrifuged at 6,000g for 20 minutes at 4C. Supernatants were extracted and further 
diluted in 3 parts of ethanol (1:3; 50% TCA: 95% ethanol). Samples were then 
quantitated fluorometrically at 620/ 680 nm (Excitation/Emission) using Biotek Synergy 
Hybrid H1 spectrophotometer (Winooski, VT). Evans blue concentration in the samples 
were evaluated using external standards for Evans blue ranging from 50-1000 ng/mL, 
prepared in same solvent (1:3; TCA: 95% ethanol). Evans blue amount in the samples 
was expressed as ng/brain cortex ± SEM. Statistical differences among groups were 
determined by one-way analysis of variance (ANOVA) followed by Bonferroni post hoc 
test to determine significant differences between specific groups. A value of p<0.05 was 
considered statistically significant. 
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RESULTS 
IL-1β treatment induces BBB endothelial cell monolayer hyperpermeability 
Endothelial cell monolayers were pretreated with various concentrations of IL-
1β ranging from 1-100 ng/mL for a 2-hour period. Result from these data confirmed that 
IL-1β treatment at 10 ng/mL for 2 hours was found to be the minimal dose to induce 
monolayer hyperpermeability (Figure 9 A; p <0.05). In a separate set of experiments, 
RBMECs were then treated with IL-1β at 10ng/mL for various time periods ranging 
from 1 to 4 hours. Result from this study further confirmed that IL-1β treatment (10 
ng/mL; 2 hours) was the minimal dose to induce RBMEC monolayer hyperpermeability 
(Figure 9 B; p <0.05). Hence, IL-1β treatment at 10 ng/mL dose for a 2-hour period was 
used to induce monolayer hyperpermeability in the following experiments. 
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Figure 9: IL-1β treatment induces dose and time dependent increase in monolayer 
hyperpermeability. In figure A, IL-1β treatment at doses 10, 50 and 100 ng/mL for 2 
hours are shown to significantly increase BBB permeability compared to the control 
group (n=4; p<0.05). Figure B indicates significant increase in IL-1β induced BBB 
permeability at 2, 3 and 4 hours compared to control (n=4; p<0.05). Monolayer 
permeability is expressed as a percentage control of FITC-dextran-10 kDa fluorescent 
intensity, plotted on the Y-axis. Data are expressed as mean ± % SEM. „*a‟ indicates 
significant increase compared to the control group. 
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MMP-9 specific inhibition attenuates IL-1β-induced BBB endothelial cell 
hyperpermeability 
Initial preliminary studies to confirm the involvement of MMPs in mediating IL-
1β-induced monolayer hyperpermeability; GM6001 (broad-spectrum MMP inhibitor) 
was used. Endothelial cell monolayers were pretreated with GM6001 (Figure 10 A; 10 
μM; 1 hour) followed by IL-1β (10 ng /mL; 2 hours). 
To study the effect of MMP-9 specific inhibition, MMP-9 inhibitor 1 and 
melatonin were employed. IL-1β (10 ng/mL; 2 hours) treatment-induced monolayer 
hyperpermeability was significantly attenuated on pretreatment with MMP-9 inhibitor 1 
(Figure 10 B; 5 nM; 1 hour) or melatonin (Figure 10 C; 10 μg/mL; 1 hour). Permeability 
was assessed by monolayer permeability assays as described earlier. 
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Figure 10: GM6001, MMP-9 inhibitor 1 and melatonin pretreatment attenuates IL-1β 
treatment-induced monolayer hyperpermeability. Figure A indicates the effect of 
GM6001 (broad-spectrum MMP inhibitor; n=4); while figure B and C employ MMP-9 
specific inhibitors: MMP-9 inhibitor 1 (n=4) and melatonin (n=6) pretreatment on IL-
1β-induced monolayer hyperpermeability. Monolayer permeability is expressed as a 
percentage control of FITC-dextran-10 kDa fluorescence intensity, plotted on Y-axis. 
Data are expressed as mean ± % SEM. „*a‟ indicates significant increase compared to 
control group; „*b‟ indicates significant decrease compared to the IL-1β treated group. 
p<0.05 was considered statistically significant.  
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MMP-9 knockdown attenuates IL-1β-induced endothelial cell hyperpermeability 
Significant contribution of MMP-9 in attenuating IL-1β-induced endothelial cell 
hyperpermeability is further supported by siRNA transfection studies. IL-1β (10 ng/mL; 
2 hours) treatment to MMP-9 knockdown (25 nM; 48 hours) cells significantly reduced 
IL-1β-induced monolayer hyperpermeability (Figure 11). siRNA treated groups were 
compared to the control siRNA group, while the IL-1β alone treated group was 
compared to the control group. 
Figure 11: Knockdown of MMP-9 by siRNA attenuates IL-1β treatment-induced 
monolayer hyperpermeability. Monolayer permeability is expressed as percentage flux 
of FITC-dextran-10 kDa fluorescence intensity, plotted on Y-axis. Data are expressed as 
mean ± % SEM. „*a‟ indicates significant increase compared to the control group; „*b‟ 
indicates significant decrease compared to the IL-1β treatment group. siRNA transfected 
groups were compared to control siRNA transfected group (n=4; p<0.05).  
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IL-1β treatment-induces MMP-9 activity 
IL-1β treatment significantly increased MMP-9 activity in RBMECs, while 
pretreatment with MMP-9 inhibitor 1 (5 nM; 1 hour) or melatonin (10 μg/mL; 1 hour) 
significantly attenuated IL-1β (10 ng/mL; 2 hours) treatment-induced MMP-9 activity 
(Figure 12 A and B). MMP-9 activity measurements were performed as described in the 
methods section. MMP-9 inhibitor 1 was used as a pharmacological inhibitor of MMP-
9, however, anti-MMP-9 properties of melatonin are still not as well-established. Our 
studies support the role of melatonin as a potential MMP-9 inhibitor. 
Figure 12: MMP-9 inhibitor 1 and melatonin pretreatment attenuates IL-1β treatment-
induced MMP-9 activity. MMP-9 inhibitor 1 (n=4) and melatonin (n=5) pretreatment 
attenuated IL-1β-induced MMP-9 activity in rat brain endothelial cells. MMP-9 activity 
is expressed as relative fluorescence units (RFU), plotted on Y-axis. Data are expressed 
as mean ± SEM. „*a‟ indicates significant increase compared to the control group; „*b‟ 
indicates significant decrease compared to the IL-1β treatment group. p<0.05 was 
considered statistically significant.  
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MMP-9 inhibition provides protection against IL-1β treatment-induced loss of 
tight junction integrity and f-actin stress fiber formation 
Cells were processed for immunofluorescence localization of tight junction 
protein, ZO-1. IL-1β (10 ng/mL; 2 hours) treatment-induced ZO-1 junctional 
discontinuity (white arrows; Panel 13 A and B) compared to the control cells. 
Pretreatment with MMP-9 inhibitor 1 (5 nM; 1 hour) and melatonin (10 μg/mL; 1 hour) 
decreased IL-1β treatment-induced ZO-1 junction integrity. Untreated cells served as 
control. These studies support that IL-1β treatment-induced monolayer 
hyperpermeability occurs via ZO-1 junctional disruption and possibly by ZO-1 
redistribution. 
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Figure 13: MMP-9 inhibitor 1 and melatonin pretreatment protects against IL-1β 
treatment-induced loss of ZO-1 junctional integrity. IL-1β treatment-induced ZO-1 
junctional disruption (white arrows) was decreased on pretreatment with MMP-9 
inhibitor 1 (n=4) and melatonin (n=4).  
Melatonin and MMP-9 inhibitor provides protection against IL-1β induced f-actin 
stress fiber formation 
For assessing the cytoskeletal assembly, rhodamine phalloidin labeling 
technique was performed. Untreated cells served as control. IL-1β treatment-induced f-
actin stress fiber formation (white arrows; Figure 14 A and B) was reduced on 
pretreatment with MMP-9 inhibitor 1 and melatonin. 
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Figure 14: MMP-9 inhibitor 1 and melatonin pretreatment reduces IL-1β treatment-
induced f-actin stress fiber formation. IL-1β treatment-induced f-actin stress fiber 
formation (white arrows) was decreased by pretreatment with MMP-9 inhibitor 1 (n=4) 
and melatonin (n=4).  
IL-1β treatment neither induces ZO-1 mRNA expression nor alters ZO-1 protein 
expression 
IL-1β treatment (10 ng/mL; 2 hours) did not alter ZO-1 or MMP-9 mRNA 
expression by RT-PCR studies (figure 15 A and B). IL-1β treatment (10 ng/mL; 2 
hours) did not the alter ZO-1 protein expression (figure 15 C). 
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Figure 15: IL-1β treatment does not induce ZO-1 mRNA or protein expression. IL-1β 
treatment neither induces ZO-1/MMP-9 mRNA expression (n=3) nor alter ZO-1 protein 
expression (n=4). RT-PCR data plotted on the Y-axis are expressed as relative 
expression of ZO-1 normalized to GAPDH. Western blot studies had 4 replicates. Data 
are represented as mean ± SEM. 
IL-1β treatment does not induce cell death in endothelial cells 
IL-1β (10 ng/mL; 2 hours) treatment did not significantly decrease the number 
of viable cells compared to the control group (Figure 16). Hydrogen peroxide (100 mM; 
2 hours) was used as a positive control.  
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Figure 16: IL-1β treatment does not induce cell death. IL-1β treatment had no effect on 
cell viability (n=5). Hydrogen peroxide (used as a positive control) treatment decreases 
cell viability significantly (p<0.05). Data are expressed as mean ± % SEM. „*a‟ 
indicates significant decrease compared to the control group.  
Melatonin pretreatment attenuates TBI-induced BBB hyperpermeability 
Mice subjected to TBI demonstrated significant increase in Evans blue leakage 
compared to the sham animals. Evans blue extravasation was performed using 
ipsilateral brain cortices. Pretreatment with melatonin attenuated mild TBI-induced 
Evans blue leakage into the brain tissue (Figure 17 A & B). Evans blue leakage was 
assessed fluorometrically at 620/680 nm (Excitation/Emission). This study suggests that 
melatonin can be used as a potential therapeutic agent in attenuating BBB 
hyperpermeability that occurs following TBI. 
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Figure 17: Melatonin pretreatment attenuates TBI-induced BBB hyperpermeability 
studied by Evans blue dye extravasation method. Pictorial representation of the brain 
tissue from various groups is shown in figure B. Sham injury group was used as the 
baseline for all comparisons. Melatonin (10 μg /gram body weight of the animal) 
pretreatment significantly attenuated TBI-induced Evans blue leakage into the 
extravascular tissue space (p<0.05). Animals were divided into sham (n=6), 
vehicle+sham (n=6), vehicle+TBI (n=5) and melatonin+TBI (n=6). Data are expressed 
as ng/brain cortex ± SEM. „*a‟ indicates significant increase compared to the sham 
injury/vehicle + sham injury group, „*b‟ indicates significant decrease compared to the 
vehicle + TBI group.  
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DISCUSSION 
Matrix metalloproteinases (MMPs) are zinc and calcium proteases that play 
several roles in vascular physiology and pathophysiology [87; 91; 92]. Matrix 
metalloproteinase-9 levels are found to increase significantly in the cerebrospinal fluid 
(CSF) samples of the traumatic brain injury patients [82]. Identification of MMP-9 in 
the CSF may indicate their role in BBB disruption, which is supported by its ability to 
degrade various tight junction proteins such as claudin-5, occludin, and zonula 
occludens (ZO-1) in cultured brain endothelial cells [83]. Although studies done in 
intracerebral hemorrhagic (ICH) models suggest that IL-1β may induce MMP-9 
activation and subsequent ZO-1 disruption [84], no elaborate studies have been done to 
imply its significance in regulating BBB dysfunction and hyperpermeability. Our 
studies further employ various MMP inhibitors like GM6001, MMP-9 inhibitor 1 and 
melatonin, in order to study the effect of MMP-9 inhibition on IL-1β-induced BBB 
dysfunction and hyperpermeability. 
Interleukin-1β upregulation is also observed following experimental brain 
injuries [84; 93]. Our studies support the contribution of IL-1β in inducing BBB 
dysfunction and hyperpermeability as demonstrated in our permeability studies, ZO-1 
junctional staining, and f-actin stress fiber formation. Although, IL-1β treatment at 10 
ng/mL for 2 hours induced ZO-1 junctional disruption and BBB hyperpermeability we 
did not see changes in the total ZO-1 protein expression. These studies indicate a 
possibility that IL-1β treatment-induced alterations in the BBB may occur via 
intermediate signaling pathways that are activated by mitogen activated protein kinases 
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like c-Jun N-terminal kinases (JNK) and p38 [74; 94]. In addition, IL-1β treatment-
induced loss of junctional integrity and f-actin stress fiber formation with no alterations 
in ZO-1 mRNA or protein expression indicate a possibility for ZO-1 protein 
relocalization. 
IL-1β treatment induces MMP-9 activity in brain endothelial cells in vitro and 
one mechanism by which MMP-9 inhibitor 1 and melatonin pretreatment attenuates IL-
1β-induced MMP-9 activity may occur by direct binding of MMP-9 inhibitor 1 and 
melatonin to MMP-9. However, these studies need to be explored further in order to 
understand how MMP-9 inhibitors inhibit IL-1β-induced BBB hyperpermeability. As 
MMP-9 is indicated to activate protein kinase C via extracellular signal-regulated 
kinases (ERK) in TBI [95], this can be a potential mechanism to explore further. Our 
studies employed pharmacological and endogenous MMP-9 inhibitors i.e. MMP-9 
inhibitor 1 and melatonin in order to test their effect on IL-1β treatment-induced BBB 
dysfunction and hyperpermeability. Use of melatonin is advantageous for our studies as 
it can cross the BBB due to its lipophilic nature and can act as a neuroprotectant [96]; 
apart from the fact that it is an inexpensive drug that is available over-the-counter with 
no known adverse effects. 
Although there is evidence that support the role of melatonin in attenuating TBI 
induced elevated ICP (1 hour post-TBI), BBB hyperpermeability and edema (72 hours 
post-TBI) [97]. Our studies further support and provide the mechanistic details for the 
observation that melatonin attenuates TBI-induced BBB hyperpermeability. Our studies 
emphasize on the significance of melatonin as a potential therapeutic agent for 
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attenuating TBI-induced BBB hyperpermeability, however, we do not believe its 
contribution is only owing to its MMP-9 inhibitory properties and these studies need 
further investigation. Future studies should aim to address the effect of melatonin on 1) 
tissue inhibitors of MMPs (TIMPs), 2) transcription factors responsible for MMP-9 
expression such as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
κB) and activator protein (AP-1), as suggested by Grossetete et al, 2009 [82], 3) on 
various ERK MAPK and 4) phosphorylation status of the tight junctions. 
In conclusion, our studies indicate that melatonin has protective effects against 
IL-1β-induced BBB dysfunction and hyperpermeability via MMP-9 mediated 
mechanisms in vitro. IL-1β-induced acute barrier dysfunctions are not due to alterations 
in the endothelial cell viability or a decrease in the content or the expression of the key 
tight junction associated protein ZO-1. Protective effects of melatonin in vitro, parallels 
with its protective effects against TBI in vivo. 
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CHAPTER III 
CALPAIN-MEDIATED MECHANISMS IN REGULATING BLOOD-BRAIN 
BARRIER DYSFUNCTION AND HYPERPERMEABILITY 
SUMMARY 
Microvascular hyperpermeability that occurs as a consequence of mechanical 
insult/pathological insult in brain leads to tissue vasogenic edema. At the cellular level, 
hyperpermeability is regulated by the tight junction proteins (TJPs); that comprise the 
blood-brain barrier (BBB). TJPs are intracellularly linked to the actin cytoskeleton via 
zonula occludens-1 (ZO-1). Calpains are shown to be involved in tight junction damage. 
However, their contribution in regulating BBB dysfunction and hyperpermeability 
following traumatic insults has not been explored. We hypothesize that calpain-
mediated mechanisms play an important role in regulating IL-1β-induced BBB 
dysfunction and hyperpermeability. 
Rat brain microvascular endothelial cell (RBMEC) monolayers were employed 
to study the effect of IL-1β treatment alone or following calpain inhibition via calpain 
inhibitor III, calpastatin, calpain-1 knockdown on monolayer hyperpermeability. 
Calpain activity following IL-1β treatment alone or following calpain inhibition by 
calpain inhibitor III was measured fluorometrically. Calcium mobilization and cell 
viability were measured following IL-1β exposure. Changes in cytoskeletal assembly 
and ZO-1 junctional integrity were assessed using immunofluorescence and rhodamine 
phalloidin labeling techniques respectively, following IL-1β treatment alone or 
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following calpain inhibitor III pretreatment. The effect of calpain inhibitor III 
pretreatment on Evans blue leakage following traumatic brain injury (TBI) was also 
assessed to study its potential effect in restoring BBB integrity.  
IL-1β-induced monolayer hyperpermeability was significantly attenuated upon 
calpain inhibition by calpain inhibitor III, calpastatin and calpain-1 siRNA (p<0.05). IL-
1β-induced calpain activity decreased significantly upon pretreatment with calpain 
inhibitor III and calpastatin (p<0.05). IL-1β treatment-induced TJ disruption and actin 
stress fiber formation were attenuated upon calpain inhibitor III pretreatment (p<0.05). 
Calpain inhibitor III pretreatment significantly attenuated TBI-induced Evans blue 
leakage in mice brain (p<0.05). 
These findings suggest that calpain-mediated mechanisms play an important role 
in promoting IL-1β-induced BBB dysfunction and hyperpermeability and its inhibition 
provided protection via the preservation of TJ integrity. Calpain inhibition provides 
protection against TBI-induced BBB hyperpermeability in a mouse model of TBI. 
Calpain inhibitor III can be a potential therapeutic target in attenuating TBI-induced 
BBB hyperpermeability when established in humans.  
 
 
INTRODUCTION 
Secondary injuries that occur following traumatic brain injury (TBI) include 
blood-brain barrier (BBB) breakdown and hyperpermeability and often result in tissue 
vasogenic edema [98]. The BBB plays an important role in maintaining the homeostasis 
of the brain. The BBB is majorly composed of the cerebral endothelial cells and the 
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tight junctions between them. Tight junctions (TJs) between the endothelial cells 
include transmembrane TJs i.e., occludin, claudins and junctional adhesion molecules 
and membrane bound TJs i.e., zonula occludens [63]. Zonula occludens play an 
important role in regulating BBB permeability by binding to both transmembrane tight 
junctions as well as actin cytoskeleton intracellularly [17]. Various mediators of 
inflammation are shown to modulate BBB permeability as described in Abbott et al, 
2000 [99]. 
Inflammation that occurs as a consequence of brain injuries is carried out by 
various pro-inflammatory cytokines [100]. IL-1β is the most implicated pro-
inflammatory cytokine in various pathologies of the central nervous system including 
TBI [101; 102]. Blocking the interleukin-1 (IL-1) has beneficial effects as demonstrated 
in experimental models of brain damage [101]. IL-1β induces BBB breakdown in rat 
brain [102] and also increases human brain microvascular endothelial cell permeability 
[103]. However, IL-1β-induced mechanisms that lead to cellular dysfunction at the level 
of BBB are widely unknown. 
We speculated the involvement of calpains in mediating BBB dysfunction and 
hyperpermeability, as they are involved in a wide array of neurological pathologies like 
trauma, ischemia-reperfusion injury, spinal cord injury and non-neurological 
pathologies [104; 105; 106; 107]. Intracellular calcium levels and the endogenous 
inhibitor of calpains namely calpastatin tightly regulate calpain levels endogenously 
[104; 108]. Calpains-1 and -2 are the predominant calpains in the central nervous 
systems [109; 110]. Calpain expression was found to increase in the endothelial cells of 
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the injured brain cortex following TBI in human patients compared to those who died 
from cardiac arrest [107]. Calpain-dependent cleavage of intracellular cytoplasmic 
protein zonula occludens-1 (ZO-1) has been studied in human lung endothelial cells 
[108]. However, their contribution in regulating BBB endothelial dysfunction and 
hyperpermeability is largely unknown. 
We hypothesize that calpain-mediated mechanisms play an important role in 
promoting IL-1β-induced BBB dysfunction and hyperpermeability and that its 
inhibition will regulate this pathway. Furthermore, we studied the effect of calpain 
inhibition on TBI-induced BBB hyperpermeability in mouse model of TBI. We aim to 
address this hypothesis by answering the following questions: 
 What is the effect of calpain inhibition on IL-1β-induced BBB endothelial
hyperpermeability, tight junctional integrity, and actin stress fiber formation? 
 Does IL-1β treatment induce calpain activity?
 Does IL-1β treatment induce intracellular calcium release?
 What is the effect of IL-1β treatment on total number of viable cells?
 Does IL-1β treatment induce ZO-1 mRNA or protein expression?
 What is the effect of calpain inhibition on TBI-induced BBB hyperpermeability in a
mouse model of TBI? 
 64 
 
MATERIALS AND METHODS 
Materials 
Rat brain microvascular endothelial cells (RBMECs) and RBMEC Medium were 
purchased from Cell Applications, Inc. (San Diego, CA).  Transwell® 24-well plates 
were obtained from Corning Costar (New York, USA). Nunc Lab Tek II-CC, 8-well 
glass chamber slides, Interleukin-1β human, fibronectin from bovine plasma, β-actin, 
albumin from bovine serum, Evans blue, trichloroacetic acid and fluorescein 
isothiocyanate-dextran-10 kDa were purchased from Sigma Aldrich (St. Louis, MO). 
Rabbit anti ZO-1 (Cat#617300), mouse anti ZO-1 (Cat#339100), 0.25% Trypsin (1X), 
Opti-MEM (1X)/reduced serum medium, Dulbecco's modified Eagle‟s medium 
(DMEM; with high glucose, HEPES, no phenol red (1X)), NuPAGE Novex® 10% Bis-
Tris protein gels, NuPAGE® MOPS SDS Running Buffer, NuPAGE® Transfer Buffer, 
HyClone Dulbecco's phosphate buffered saline (PBS, without calcium, magnesium, or 
phenol red), TRIzol® Reagent, SuperScript® IV First-Strand Synthesis System, Halt® 
Protease Inhibitor Cocktail (100X), Pierce™ ECL Western Blotting substrate and 
rhodamine phalloidin were purchased from Thermo Fisher Scientific (Carlsbad, CA). 
Goat anti-mouse IgG-HRP and donkey anti-rabbit IgG-FITC secondary antibodies were 
purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Calpain Activity 
Fluorometric Assay Kit (K240-100) and EZViable™ Calcein AM Cell Viability 
fluorometric assay kit were bought from Biovision (Milpitas, CA). We also purchased 
Vector VECTASHIELD® Mounting Media with DAPI from Vector Laboratories 
(Burlingame, CA). Pierce™ BCA Protein Assay Kit and RT² qPCR Primer Assay for 
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Mouse GAPDH were purchased from Qiagen (Valencia, CA). Carbobenzoxy-valinyl-
phenylalaninal, also called as Calpain Inhibitor III or MDL 28170 was bought from 
Calbiochem (Billerica, MA). Cell Lysis Buffer (10X) was bought from Cell Signaling 
Technology, Inc. (Danvers, MA). Primers were purchased from Thermo Fisher 
Scientific (Carlsbad, CA). Calpain-1 siRNA and control siRNA (ON-TARGETplus 
siRNA) were purchased from Dharmacon, General Electric (Pittsburgh, PA). 
In vitro BBB model 
Primary cultures of RBMECs derived from the brain of adult Sprague Dawley 
rat were purchased from the Cell Applications Inc. (San Diego, CA). RBMECs were 
initially grown on 0.05% fibronectin-coated cell culture dishes, using the RBMEC 
medium in a cell culture incubator (95% O2, 5% CO2 at 37°C). RBMECs were treated 
with 0.25% trypsin-EDTA for cell detachment. Detached cells were then grown on 
fibronectin-coated Transwell® inserts, chamber slides or 100 mm dishes for 
experimental purposes. RBMEC passages 8-10 were chosen for all the experiments. 
Animals and surgeries 
C57BL/6 mice (25-30 g) were obtained from Charles River Laboratories 
(Wilmington, MA). Animals were maintained at the Texas A&M University Health 
Science Center College of Medicine and Baylor Scott and White Health animal facility 
on a 12:12 hour dark/light cycle, with free access to food and water. The room 
temperature was maintained at 25° ± 2 °C. Surgical and experimental procedures used 
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in this study were conducted after approval by the Institutional Animal Care and Use 
Committee. The facility is approved by the Association for Assessment and 
Accreditation of Laboratory Animal Care International in accordance with the National 
Institutes of Health guidelines. 
Craniotomy procedure 
The head of the animal was shaven and the surgical site on the surface of the 
head was cleaned with an alcohol wipe. Lubricating ointment was applied to the eyes. A 
midline incision was made to remove the skin from top of the skull exposing the sagittal 
suture, bregma and lambda. A circular craniotomy window, 3-4 mm in diameter was 
made on ipsilateral hemisphere, between lambda and bregma using a microdrill. The 
resulting bone flap was removed. Sham animals received only craniotomy surgery, 
while TBI injury group receives brain injury via controlled cortical impactor following 
craniotomy procedure. 
Controlled cortical impact 
Benchmark™ Stereotaxic Impactor from Leica was used for these studies. 
Following craniotomy procedure, the animal was mounted on the stereotaxic frame. An 
impactor probe of 3 mm diameter was used to impact the exposed part of the brain. The 
depth of the injury was used to determine the intensity of the injury. Settings for mild 
TBI used in this study are: 2 millimeters depth, 0.5 meters/second velocity and 100 
milliseconds contact time as described in Chen et al, 2014 [88]. 
67 
Monolayer permeability assays 
RBMECs were grown on fibronectin-coated Transwell® inserts as monolayers 
for 72-96 hours and regularly checked for confluency. Monolayers were initially 
exposed to phenol red free DMEM for 45 minutes to an hour. DMEM treated cells were 
then pretreated with calpain inhibitors and subsequently with IL-1β (10 ng/mL; 2 
hours). At the end of the treatments, FITC labeled dextran-10 kDa (5 mg/mL; 30 
minutes) was applied to the luminal compartment. One hundred microliters of sample 
was collected from the abluminal compartment at the end of 30 minutes and measured 
fluorometrically at 485/520 nm (Excitation/Emission) using Fluoroskan Ascent™ FL 
Microplate Fluorometer and Luminometer (Vantaa, Finland). 
Calpain inhibitor III (10 μM; 1 hour) was used for pharmacological inhibition of 
calpains, while calpastatin (10 μM; 1 hour), was used for endogenous inhibition of 
calpains. Calpain inhibitor III (MDL-28170; Carbobenzoxy-valinyl-phenylalaninal; 
Cbz-Val-Phe-H) is a potent, cell permeable inhibitor of both calpain-1 and -2 and 
calpastatin is a cell-permeable peptide (27 amino acids in length) that inhibits both 
calpains-1 and -2. 
Untreated cells served as control. Each experiment was repeated four times. 
Fluorescence intensity was plotted on the Y-axis and represented as % control. Data 
were expressed as mean ± % SEM and statistical differences among groups were 
determined by one-way analysis of variance (ANOVA) followed by Bonferroni post hoc 
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test to determine significant differences between specific groups. A value of p<0.05 was 
considered statistically significant. 
 
 
Calpain-1 knockdown studies 
RBMECs were grown on fibronectin-coated Transwell® inserts as monolayers 
for 72-96 hours. Cells were transfected with control siRNA or calpain-1 siRNA on the 
following day or until they are about 50% confluent. RBMEC monolayers were 
transfected with calpain-1 and control siRNA at 25 nM concentration for 48 hours. 
Transfection was performed according to manufacturer‟s instructions. Transfected 
monolayers were then exposed to IL-1β and permeability was determined based on the 
leakage of FITC-dextran-10 kDa (5 mg/mL; 30 minutes) leakage from the luminal to the 
abluminal chamber. One hundred microliters of the sample was obtained from the 
abluminal chamber and measured fluorometrically at 485/520 nm (Excitation/Emission) 
using Fluoroskan Ascent™ FL Microplate Fluorometer and Luminometer. Untreated 
cells were used as control. Each experiment was repeated four times. Fluorescence 
intensity was plotted on the Y-axis and represented as % control. Data were expressed 
as mean ± % SEM and statistical differences among groups were determined by one-
way analysis of variance (ANOVA) followed by Bonferroni post hoc test to determine 
significant differences between specific groups. A value of p<0.05 was considered 
statistically significant. 
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Calpain activity measurement 
A Calpain Activity Fluorometric Assay Kit was used to measure the calpain 
activity in the cells. For this assay, RBMECs were grown in petri dishes until 
confluency is achieved. Cells were then trypsinized using lysis buffer, followed by 
resuspension in extraction buffer provided in the kit. The kit employs a synthetic calpain 
substrate, Ac-Leu-Leu-Tyr-7-Amino-4-trifluoromethylcoumarin (Ac-LLY-AFC) in 
order to detect the calpain activity. Equal amount of protein lysates were taken and 
subsequently exposed to the substrate Ac-LLY-AFC and incubated in the dark for an 
hour. Samples were then read using Fluoroskan Ascent™ FL microplate fluorometer 
and luminometer at 400/505 nm (Excitation/Emission).  
Cells lysates were pretreated with calpain inhibitors (Calpain inhibitor III and 
calpastatin at 10 μM for 1 hour) and subsequently with IL-1β treatment. Untreated cells 
served as control. Each experiment was repeated five times. Calpain activity was 
expressed as relative fluorescence units (RFU) and plotted on the Y-axis. Data were 
expressed as mean ± SEM and statistical differences among groups were determined by 
one-way analysis of variance (ANOVA) followed by Bonferroni post hoc test to 
determine significant differences between specific groups. A value of p<0.05 was 
considered statistically significant. 
 
 
Immunofluorescence localization and cytoskeletal assembly labeling  
Zonula occludens (ZO-1) junctional localization and f-actin stress fiber 
formation were assessed. RBMECs were grown on chamber slides for overnight. 
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Pretreatment with calpain inhibitor III (10 μM; 1 hour) was followed by IL-1β treatment 
(10 ng/mL; 2 hours). Cells were then fixed in 4% paraformaldehyde in PBS for 10-15 
minutes and permeabilized with 0.5% Triton-X 100 in PBS for another 10-15 minutes. 
Cells were blocked with 2% bovine serum albumin (BSA) in PBS for an hour at room 
temperature. Cells were then incubated overnight with anti-rabbit primary antibodies 
against ZO-1 (#617300) at 1:150 dilution, followed by incubation with anti-rabbit IgG-
FITC conjugated secondary antibody for an hour at room temperature. Cells were then 
washed and mounted.  
Following treatment study, cells were fixed, permeabilized and blocked in 2% 
BSA-PBS as described earlier. Cells were then labeled with rhodamine phalloidin at 
1:50 dilution in 2% BSA-PBS for 20 minutes. Chamber slides were then washed and 
mounted using VECTASHIELDd® Antifade Mounting Media with DAPI for nuclear 
staining. Cells were visualized and scanned at a single optical plane with an Olympus 
Fluoview 300 Confocal Microscope (Center Valley, PA) with a PLA PO 60X water 
immersion objective. Untreated cells served as control. Each experiment was repeated 
four times.  
 
 
Quantitative real time-PCR 
RBMECs were grown on 100 mm cell culture dishes; total RNA was then 
extracted from the cells using TRIzol® reagent according to the manufacturer‟s 
instructions. RNA concentration and quality were determined by employing the ratio of 
absorbance at 260/280 nm using Biotek Synergy Hybrid Spectrophotometer (Winooski, 
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VT).  Reverse transcription was performed using the SuperScript® IV First-Strand 
Synthesis System. Quantitative real time PCR was performed using the RT² SYBR 
Green Fluor qPCR Mastermix with the following primer pairs for ZO-1: Forward 
primer: 5′-CCTCTGATCATTCCACACAGTC-3′, Reverse primer: 5′-
TAGACATGCGCTCTTCCTCTCT-3′, and GAPDH: Forward primer: 5′-
AATGTATCCGTTGTGGATCT-3′, Reverse primer: 5′-
CAAGAAGGTGGTGAAGCAGG-3′ were used. Real-time PCR detection was carried 
out using Stratagene Mx3000P qPCR System, Agilent Technologies (La Jolla, CA), 
using 1 μL of cDNA for 10 minutes at 95°C, followed by 40 cycles of 15 sec at 95°C 
for denaturation and 1 min at 60°C for annealing. Relative abundances of target genes 
were calculated by normalizing Ct values to endogenous control glyceraldehyde 3-
phosphate dehydrogenase (GAPDH).  
Cells were divided into 2 groups: control (untreated) and IL-1β (10 ng/mL; 2 
hours) treatment groups. Each experiment was repeated three times. Relative mRNA 
expression of ZO-1 was obtained by normalizing the Ct values to the endogenous 
control GAPDH for each repeat. Normalized Ct values were expressed as mean ± SEM. 
Statistical differences among groups were determined by one-way analysis of variance 
(ANOVA) followed by Bonferroni post hoc test to determine significant differences 
between specific groups. A value of p<0.05 was considered statistically significant. 
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Western blot assays 
Western blot analysis was performed to investigate the expression of ZO-1 
protein in RBMECs. Following treatment studies, cells were washed twice in ice-cold 
PBS and incubated in ice-cold cell lysis buffer (1X) along with protease inhibitor 
cocktail (1X) for 5 minutes in cell culture dishes. Cells were then scraped, sonicated and 
centrifuged at 14,000g for 10 minutes at 4C. Supernatant was collected from the 
extracts and protein concentration was determined using protein assay kit. Equal 
amounts of total protein (50 μg) were separated by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) on 10% Bis-Tris precast gels at 
constant voltage (145 V) for 180 minutes. Proteins were then transferred onto the 
nitrocellulose membrane at constant voltage (30 V) for overnight and the membranes 
were blocked using 5% nonfat dry milk in Tris-Buffered Saline (TBS) with 0.05% 
Tween-20 for 3 hours and subsequently incubated with primary mouse monoclonal anti 
ZO-1 antibody (1:250 dilution). Membranes were washed thrice in TBS-T and 
incubated with the goat anti-mouse IgG-HRP conjugated secondary antibody. After 
washing, the immunoblots were visualized by ECL Western Blotting Substrate. Cells 
were divided into untreated (control) and IL-1β (10 ng/mL; 2 hours) treatment groups. 
Each experiment was repeated four times. Equal amount of protein sample loading was 
verified by assessing β-actin protein expression. Each experiment was repeated four 
times. 
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Cell viability studies 
An EZViable™ Calcein AM Cell Viability Assay Kit (Fluorometric) was used 
for quantify the number of viable cells. Calcein AM is a non-fluorescent, hydrophobic 
compound that easily penetrates intact and live cells. Hydrolysis of the calcein AM by 
intracellular esterase produces a hydrophilic, strongly fluorescent compound that is 
retained in the cell cytoplasm, which can be measured at 485/530 nm 
(Excitation/Emission).  
Equal numbers of cells were grown on sterile black 96 well trays. On reaching 
confluency, growth media was discarded and cells were washed in PBS and pre-exposed 
to phenol red-free medium for an hour. Cells were divided into control (untreated) and 
IL-1β (10 ng/mL) treatment groups. Cells were treated with IL-1β for 2, 4 and 6 hours 
with hydrogen peroxide at 50, 25, 10 mM respectively, as a positive control. Following 
treatments, cells were then exposed to calcein buffer solution (calcein AM: calcein 
dilution buffer in 1:500 dilution) and incubated at 37C for 30 minutes and a 
fluorometric reading was obtained.  
Each experiment was repeated five times. Fluorescence intensity was plotted on 
the Y-axis and represented as % control. Data were expressed as mean ± % SEM and 
statistical differences among groups were determined by one-way analysis of variance 
(ANOVA) followed by Bonferroni post hoc test to determine significant differences 
between specific groups. A value of p<0.05 was considered statistically significant. 
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Fluo-4 based [Ca
2+
]i measurements 
For population measurements, RBMECs (monolayer) were incubated with 5 μM 
Fluo-4 AM (Thermo Fisher Scientific, Carlsbad, CA) at 37C for 40 minutes and Fluo-4 
fluorescence intensity was measured through a Biotek Synergy Hybrid 
Spectrophotometer (Winooski, VT). Ionomycin (Iono, 1 μM) and thapsigargin (TG, 2 
μM) were used to increase [Ca2+]i as positive controls. DMSO was used as a vehicle 
control.  Each experiment was repeated four times. Data were presented as mean ± S.E. 
 
 
Single-cell [Ca
2+
]i imaging 
RBMECs were grown on cover slips and incubated with 2 μM Fura-2 AM 
(ThermoFisher Scientific, Carlsbad, CA) in the culture medium at 37C for 40 minutes. 
Ratiometric [Ca
2+
]i imaging was performed on an IX-81 microscope (Olympus) based 
system as described previously from individual cells [111]. Data were analyzed using 
Metafluor software (Universal imaging) and OriginPro 8 software (Origin Lab) and 
expressed as mean ± S.E.  
 
 
Evans blue leakage studies  
Evans blue dye binds to albumin in the blood enabling us to study the vascular 
leakage into the extravascular tissue following TBI. For this study, C57BL/6 mice (25-
30 g) were anesthetized with urethane, i.p. injection (2 mL/kg body weight) followed by 
Evans blue dye, i.v. injection (2% wt/vol in saline; 4 mL/kg body weight). Evans blue 
was allowed to circulate in the animal for 30 minutes prior to performing sham surgery 
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(only craniotomy) or TBI using controlled cortical impactor. Drugs were given to the 
animal along with Evans blue injection and allowed to circulate for 30 minutes as well. 
DMSO was used a vehicle control. Settings for mild TBI are described in the CCI 
procedure.  
Animals were grouped into Sham (only craniotomy), Vehicle + Sham (DMSO 
injection followed by craniotomy), Vehicle + TBI group (DMSO followed by mild 
TBI), and Calpain inhibitor III+TBI group (calpain inhibitor III [10 μg/gram body 
weight of the animal] injection followed by mild TBI). Each group consisted of five 
animals. 
One-hour post-TBI, animals were transcardially perfused with sterile saline 
containing heparin (1000 U/mL) for at least 20 minutes. Brains were extracted and brain 
cortex was carefully separated and weighed. Brain cortices were then homogenized in 1 
mL of 50% (wt/vol) trichloroacetic acid (TCA) in saline. Homogenate was then 
centrifuged at 6,000g for 20 minutes at 4C. Supernatants were extracted and diluted in 
3 parts of ethanol (1:3; 50% TCA: 95% ethanol). Samples were then quantitated 
fluorometrically at 620/680 nm (Excitation/Emission) using Biotek Synergy Hybrid H1 
spectrophotometer (Winooski, VT). Evans blue concentration in the samples were 
evaluated using external standards for Evans blue ranging from 50-1000 ng/mL, 
prepared in same solvent (1:3; TCA: 95% ethanol). Evans blue amount in the samples 
were expressed as ng/brain cortex ± SEM. Statistical differences among groups were 
determined by one-way analysis of variance (ANOVA) followed by Bonferroni post hoc 
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test to determine significant differences between specific groups. A value of p<0.05 was 
considered statistically significant. 
 
 
RESULTS 
Pharmacological or endogenous calpain inhibition attenuates IL-1β-induced 
endothelial cell hyperpermeability 
RBMEC monolayers were pretreated with calpain inhibitor III or calpastatin to 
confirm the contribution of calpains in mediating IL-1β (10 ng /mL for 2 hours)-induced 
endothelial cell hyperpermeability. Figure 18 demonstrates that IL-1β treatment 
significantly increases endothelial cell hyperpermeability, while pretreatment with 
calpain inhibitor III (Figure 18 A, p <0.05) and calpastatin (Figure 18 B, p <0.05) 
significantly attenuates IL-1β-induced endothelial cell hyperpermeability.  
 
 
 
77 
Figure 18: Calpain inhibitor III and calpastatin pretreatment attenuates IL-1β treatment-
induced monolayer hyperpermeability. Calpain inhibitor III (figure A; n=4; p<0.05) and 
calpastatin (figure B; n=4; p<0.05) pretreatment attenuates IL-1β-induced monolayer 
hyperpermeability significantly. Monolayer permeability is expressed as a percentage 
control of FITC-dextran-10 kDa fluorescence intensity, plotted on Y-axis. Data are 
expressed as mean ± % SEM. „*a‟ indicates significant increase compared to the control 
group; „*b‟ indicates significant decrease compared to the IL-1β treatment group.  
Calpain-1 knockdown attenuates IL-1β-induced endothelial cell hyperpermeability 
Significant contribution of calpains-1 is further supported by calpain-1 siRNA 
transfection studies. Figure 19 demonstrates that IL-1β treatment-induced endothelial 
cell hyperpermeability was significantly reduced in calpain-1 knockdown cells 
compared to IL-1β treatment alone (p <0.05). Calpain-1 knockdown studies were 
performed using siRNA transfection technique as described earlier. siRNA treated 
groups were compared to the control siRNA group, while the IL-1β alone treated group 
was compared to the control group. 
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Figure 19: Knockdown of calpain-1 by siRNA attenuates IL-1β treatment-induced 
monolayer hyperpermeability. Monolayer permeability is expressed as percentage flux 
of FITC-dextran-10 kDa fluorescence intensity, plotted on Y-axis. Data are expressed as 
mean ± % SEM. „*a‟ indicates significant increase compared to the control group; „*b‟ 
indicates significant decrease compared to the IL-1β treatment group (n=4; p<0.05).  
IL-1β treatment-induces calpain activity 
IL-1β treatment significantly increased calpain activity in RBMECs, while 
pretreatment with calpain inhibitor III and calpastatin significantly attenuated IL-1β-
induced calpain activity (Figure 20, p <0.05). Calpain activity measurements were 
performed as described in the methods section. 
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Figure 20: Calpastatin and calpain inhibitor III pretreatment attenuates IL-1β treatment-
induced calpain activity. Calpain activity is expressed as relative fluorescence units 
(RFU), plotted on Y-axis. Data are expressed as mean ± SEM. „*a‟ indicates significant 
increase compared to the control group; „*b‟ indicates significant decrease compared to 
the IL-1β treatment group (n=4; p<0.05).  
Calpain inhibition provides protection against IL-1β-induced loss of tight junction 
integrity and f-actin stress fiber formation. 
Cells were processed for immunofluorescence localization of tight junction 
protein, ZO-1. IL-1β treatment-induced ZO-1 junctional discontinuity (white arrows; 
Panel 21 A) compared to the control cells. Pretreatment with calpain inhibitor III (10 
μM; 1 hour) decreased IL-1β (10 ng/mL; 2 hours)-induced ZO-1 junction integrity. 
For assessing the cytoskeletal assembly, rhodamine phalloidin labeling 
technique was performed. Untreated cells served as control. IL-1β (10 ng/mL; 2 hours) 
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treatment-induced f-actin stress fiber formation (white arrows; Figure 21 B) was 
reduced by pretreatment with calpain inhibitor III (10 μM; 1 hour). 
Figure 21: IL-1β treatment-induced ZO-1 junctional disruption and f-actin stress fiber 
formation is reduced by pretreatment with calpain inhibitor III. IL-1β treatment-induced 
ZO-1 junctional disruption and f-actin stress fiber formation are shown by white arrows 
in panel A and B respectively. ZO-1 junctional integrity and f-actin stress fiber 
formation were assessed using immunofluorescence localization and rhodamine 
phalloidin techniques respectively (n=4 for each study). 
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IL-1β treatment neither induces ZO-1 mRNA expression nor alters ZO-1 protein 
expression 
IL-1β (10 ng/mL; 2 hours) treatment did not alter ZO-1 or MMP-9 mRNA 
expression by RT-PCR studies. IL-1β treatment did not alter ZO-1 protein expression. 
Figure 22: IL-1β treatment does not induce ZO-1 mRNA or protein expression. 
Fluorescence intensity from RT-PCR studies is expressed as relative expression of ZO-1 
normalized to GAPDH and is plotted on Y-axis (n=3; figure A). Data are represented as 
mean ± SEM. ZO-1 protein expression did not change following IL-1β treatment (n=4; 
figure B).  
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IL-1β treatment does not induce cell death 
IL-1β treatment did not significantly decrease the number of viable cells 
compared to the control group, as shown in Figure 23. Hydrogen peroxide (100 mM) 
was used as a positive control.  
Figure 23: IL-1β treatment does not induce cell death. IL-1β treatment did not alter cell 
viability up to 4 hours. Treatment of hydrogen peroxide used as a positive control 
showed a significant decrease in cell viability compared to the untreated and IL-1β 
treatment groups (n=5; p<0.05). Data are expressed as mean ± % SEM. „*a‟ indicates 
significant decrease compared to the control group.  
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IL-1β treatment does not induce intracellular calcium mobilization 
To test whether IL-1β upregulates the activity of calpains, a calcium-dependent 
cysteine protease, by increasing intracellular calcium concentration ([Ca
2+
]i), we directly
measured [Ca
2+
]i in RBMECs by two different approaches. Initially, RBMECs were
grown as monolayers and loaded with Fluo-4 AM (a Ca
2+
 indicator). Fluo-4 signals
were measured from cells before (F0) and after (F) a 10-minute incubation of cells with 
IL-1β (10 ng/mL). In parallel, control cells were treated with thapsigargin (TG; 2 µM), 
ionomycin (Iono; 1 µM), or DMSO as the vehicle control for TG and Iono. TG is a 
sarco/endoplasmic reticulum Ca
2+
-ATPase (SERCA) pump inhibitor, which passively
depletes Ca
2+
 in the ER store in conjunction with triggering store-operated Ca
2+
 entry
(SOCE). Ionomycin is an ionophore that increases membrane permeability to Ca
2+
,
therefore raising the intracellular level of Ca
2+
. As expected, both stimulations by TG
and ionomycin triggered a significant increase of [Ca
2+
]i (Figure 24 A); however, there
was only a negligible intracellular Ca
2+
 response to the IL-1β treatment (Figure 24 A).
It is possible that IL-1β triggers a relatively transient [Ca2+]i response and/or a
small population of cultured RBMECs has a dramatic [Ca
2+
]i response to IL-1β, which
could be masked during our Fluo-4 based [Ca
2+
]i measurement. Accordingly, RBMECs
were then loaded with Fura-2 AM, a ratiometric Ca
2+
 indicator, and [Ca
2+
]i was
continuously monitored at the single-cell level (15 seconds/frame). In the control 
experiments, TG could evoke a typical SOCE in RBMECs (Figure 24 B) that elevates 
[Ca
2+
]i from 65 ± 6 nM up to 281 ± 22 nM (Figure 24 D). However, when RBMECs
were incubated with 10 ng/mL IL-1β for 20 minutes, there were no cells showing 
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significantly increased [Ca
2+
]i (data not shown). We then treated cells with a higher dose
(100ng/mL) of IL-1β for 2 hours, which still did not significantly promote intracellular 
calcium levels in any cells (Figure 24 C and 24 D). As a conclusion, our results indicate 
that IL-1β treatment does not induce a dramatic [Ca2+]i mobilization in RBMECs.
Figure 24: IL-1β treatment does not induce intracellular calcium mobilization. Figure A 
demonstrates the effect of IL-1β treatment on intracellular calcium mobilization (F) 
relative to basal Ca
2+
 (F0) when measured 10 minutes after the application of DMSO
(vehicle control), IL-1β (10 ng/mL), TG (2 µM), and Iono (1 µM), and displayed as 
mean ± SE (n = 4). Figure B and C are the representative intracellular free calcium 
recordings ([Ca
2+
]i, mean ± SE) showing cytosolic Ca
2+
 levels coupled to TG (2 µM,
figure B) or IL-1β (100 ng/mL, C) stimulation. The top bars indicate the type of 
extracellular solutions applied to the RBMECs, and the vertical lines on the X-axis 
indicate the time of solution change. Figure D displays averaged peak value of [Ca
2+
]i in
response to TG (n = 40 cells) and IL-1β (n = 30 cells), respectively, are summarized. 
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Calpain inhibitor III pretreatment attenuates TBI-induced BBB 
hyperpermeability 
Mice subjected to TBI demonstrated significant increase in Evans blue leakage 
compared to the sham animals. Pretreatment with calpain inhibitor III attenuated mild 
TBI-induced Evans blue leakage into the brain tissue (Figure 25 A & B; p <0.05). Evans 
blue leakage was assessed fluorometrically at 620/680 nm (Excitation/Emission). This 
study suggests that calpains are a potential therapeutic target to attenuate BBB 
hyperpermeability that occurs following TBI.  
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Figure 25: Calpain inhibitor III pretreatment attenuates TBI-induced BBB 
hyperpermeability studied by Evans blue dye extravasation method. Vehicle control 
group subjected to TBI demonstrated significant increase in Evans blue leakage 
compared to the sham injury group (figure A; p<0.05). Calpain inhibitor III (10 μg 
/gram body weight of the animal) pretreatment significantly attenuated TBI-induced 
Evans blue leakage into the extravascular tissue space (figure A; p<0.05). Pictorial 
representation of the brain tissue from various groups is shown in figure B. Each group 
consisted of five animals. Sham injury group is used as the baseline for all comparisons. 
Data are expressed as ng/brain cortex ± SEM. „*a‟ indicates significant increase 
compared to the sham injury group; „*b‟ indicates significant decrease compared to the 
vehicle + TBI group. 
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DISCUSSION 
The major findings of this study are: 1) calpain(s) promote BBB dysfunction and 
hyperpermeability via disruption of the TJs in vitro, 2) IL-1β is an inducer of calpain-
mediated BBB dysfunction and hyperpermeability in vitro, 3) inhibition of calpain 
activation provides protection against BBB hyperpermeability via preservation of TJ 
integrity in vitro, 4) calpain mediated loss of barrier functions are independent of Ca
2+
mobilization or loss of cell viability, and 5) pharmacological inhibition of calpains 
provide protection against BBB hyperpermeability in a mouse model of TBI. 
Calpains are thiol or cysteine proteases that are present in most of the 
mammalian cells. Under physiological conditions, calpains possess low activity and 
play an important role in regulating the kinases, transcription factors, and receptors 
apart from aiding in the cytoskeletal turnover [112]. Calpain deficiencies as well as its 
over activation are linked to a variety of diseases and pathological consequences 
described in Kampfl et al, 1997 [113]. Due to their multifaceted nature, they control 
various irreversible signaling events and other biological functions in the cell like 
endothelial cell adhesion, differentiation, migration, proliferation, cell cycle control, 
cytoskeletal remodeling, embryonic development, vesicular trafficking [107; 108; 109; 
114; 115; 116]. Calpain-1 (also known as tau-calpain) and calpain-2 (also known as m-
calpain) are predominantly expressed in the central and peripheral nervous systems 
[109; 110]. Calpain-1 is activated under low calcium concentrations (3-50 μM), while 
calpain-2 is activated only under high concentrations (400-800 μM) of calcium in the 
cell [115; 116]. Calpain knockdown data from our studies demonstrates the contribution 
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of calpain-1 but we do not disregard the contribution of calpain-2 in mediating BBB 
dysfunction and hyperpermeability and is an area open for further investigation. 
Calpastatin and intracellular Ca
2+
 levels tightly regulate the calpain levels
endogenously [107; 113]. This information was used to study the contribution of 
calcium and calpastatin in regulating IL-1β-induced endothelial hyperpermeability. To 
study the effect of IL-1β treatment on intracellular calcium, we performed calcium 
mobilization studies, which demonstrated that IL-1β treatment (10 ng/mL; 2 hours) does 
not induce significant intracellular mobilization of calcium in RBMECs. However, we 
do not rule out the possible involvement of calcium in inducing calpains as established 
in several other conditions. We speculate that IL-1β-induced calpain activation may 
occur due to changes in localized calcium, which can be studied by calcium sparks 
[117]. Calpastatin is an endogenous inhibitor of calpains; it regulates the activity of 
calpains by binding to the active site cleft of both calpains-1 and -2. Our results support 
the significance of calpain-calpastatin interactions in regulating BBB functions. 
Although, our studies demonstrate the ability of calpastatin in attenuating IL-1β-induced 
endothelial hyperpermeability, we have not further explored these studies in vivo. 
Understanding calpastatin-mediated regulation of BBB hyperpermeability can open new 
avenues for finding therapeutic agents that can alter the secondary injuries that occur 
following brain injury. 
We have shown that pharmacological inhibition of calpains is effective in 
preserving barrier functions in vitro and in vivo. Calpain inhibitor III, is a well-studied 
cell permeable pharmacological inhibitor of calpains [107], was chosen for our in vitro 
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and in vivo studies. Calpain inhibitor III crosses the BBB efficiently and binds 
specifically to calpains -1 and -2, unlike other inhibitors of calpains like trypsin, 
plasmin, caspase-1, and cathepsin D [116]. Cytoskeletal and neuroprotective properties 
of calpain inhibitor III were examined using the controlled cortical impact (CCI) model 
of TBI in male CF-1 mice, 24 h post-TBI [118]. However, these studies do not aim to 
understand the effect of calpain inhibitor III on TBI-induced BBB hyperpermeability. 
Our study addresses this important question. While our in vitro studies support that 
calpain inhibition protected the BBB by preserving the TJ integrity and cytoskeletal 
organization this has not been confirmed in our in vivo studies. 
Studies by Tsubokawa et al., 2006 indicate a link between calpain, cathepsin B, 
and matrix metalloproteinase-9 (MMP-9) upregulation [119]. MMP-2 and calpains have 
some common cleavage targets like sarcomeric proteins troponin I, myosin light chain-1 
and titin in heart cells [120]. These studies support the possibility that calpain-induced 
BBB endothelial cell hyperpermeability may occur via MMP activation or vice-versa. 
Understanding this relationship is important to selectively target the appropriate 
pathways for therapeutic purposes. Our results demonstrate changes in cytoskeletal 
assembly evidenced by increased f-actin stress fiber formation following IL-1β 
treatment-induced calpain activation and BBB hyperpermeability. The stress fiber 
formation that occurs following IL-1β treatment may also involve tight junction 
cleavage via Ras homolog gene family, member A (RhoA)-dependent mechanisms 
leading to BBB permeability. RhoA-mediated mechanisms also activate cell division 
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control protein (cdc42) activation, which play an important role in maintaining the tight 
junction integrity and actin cytoskeletal assembly [121].  
Our studies on understanding the role of calpains were focused more on the tight 
junction protein, ZO-1 and the actin cytoskeleton. However, understanding the 
contribution of calpains in mediating BBB hyperpermeability is extremely complicated 
as they target a wide range of proteins, which include: cytoskeletal proteins (α-spectrin, 
talin, filamin, paxillin, vinculin, ezrin, microtubule-associated proteins 2, myristoylated 
alanine-rich C-kinase substrate and neurofilament proteins), kinases (PP60 and proto-
oncogene tyrosine-protein kinase src), phosphatases (protein tyrosine phosphatase 1B, 
focal adhesion kinase, talin, paxillin, protein tyrosine phosphatase), membrane–
associated proteins, junctional proteins (β-catenin, E-cadherin, β-spectrin), and 
transcription factors such as c-fos, c-jun and p53 [108; 113; 114; 122; 123; 124; 125]. 
Although these molecules may not be expressed in the BBB, it is important to know 
how calpains interact with them and how these molecules contribute to BBB 
dysfunction or trauma-induced brain damage directly or indirectly. 
In conclusion, our studies demonstrate the novel role of calpains in promoting 
IL-1β-induced BBB dysfunction and hyperpermeability and how calpain inhibition 
regulates this pathway. Our results further demonstrate that calpain inhibition has the 
potential to develop as a therapeutic target in controlling TBI-induced BBB 
hyperpermeability and edema when established in human patients.  
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CHAPTER IV 
P2X7R-MEDIATED MECHANISMS IN REGULATING BLOOD-BRAIN 
BARRIER DYSFUNCTION AND HYPERPERMEABILITY 
SUMMARY 
Traumatic brain injury (TBI) is a serious cause of morbidity and mortality 
worldwide. Pathological consequences that occur following TBI include blood-brain 
barrier (BBB) dysfunction and hyperpermeability leading to vasogenic edema. 
Structurally, the BBB is comprised of brain endothelial cells and the tight junctions (TJ) 
between them, consisting of tight junction proteins (TJPs). Of these proteins, zonula 
occludens-1 (ZO-1) is an important scaffolding linker molecule that binds the 
transmembrane tight junctions to the actin cytoskeletal assembly of the cell. It plays an 
important role in regulating BBB hyperpermeability. Extracellular or intracellular 
factors that alter TJ integrity will promote BBB hyperpermeability.  Traditionally, 
adenosine triphosphate (ATP) is known as a major source of energy in cell; however, 
ATP when released into extracellular space due to trauma or other reasons acts as a 
danger signal by acting via purinergic receptor (P2X7R). The objective of this study 
was to understand the role of P2X7R-mediated mechanisms in regulating BBB 
dysfunction and hyperpermeability using in vitro and in vivo approaches. 
Rat brain endothelial cells (RBMEC) were used for the in vitro studies. 
Monolayer permeability assays using Transwell inserts were employed to determine the 
minimal concentration of Bz-ATP (potent agonist of P2X7R) to induce 
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hyperpermeability. Effect of Bz-ATP treatment alone or following P2X7R inhibition via 
A740003 or P2X7R siRNA on monolayer hyperpermeability was assessed. Changes in 
ZO-1 tight junctional localization and f-actin stress fiber formation following Bz-ATP 
treatment alone and following A740003 pretreatment were assessed via 
immunofluorescence and rhodamine phalloidin labeling respectively. Effect of Bz-ATP 
treatment on cell viability, ZO-1 mRNA, and protein expression were assessed by 
fluorescence assays, RT-PCR and western blot respectively. Evans blue extravasation 
assays and Intravital microscopy imaging techniques were employed to study the effect 
of TBI-induced BBB dysfunction in P2X7R knock out and wild type mice. Also, the 
effect of KN-62 (non-competitive P2X7R antagonist) pretreatment on TBI-induced 
BBB hyperpermeability was determined by Evans blue extravasation assays. Bz-ATP-
induced monolayer hyperpermeability was attenuated by pretreatment with P2X7R 
inhibitors or transfection with P2X7R siRNA. Bz-ATP-induced disruption of tight 
junction integrity and f-actin stress fiber formation was attenuated by pretreatment with 
A740003. P2X7R knockout mice demonstrated less leakage of Evans blue and FITC-
dextran into extravascular space compared to the wild type mice subjected to TBI. KN-
62 pretreatment attenuated TBI-induced Evans blue leakage in mice. 
Together, these findings implicate that ATP-sensitive P2X7R facilitates BBB 
hyperpermeability via alterations in TJ integrity and ZO-1 protein levels. P2X7R may 
be further studied as a novel therapeutic target to control TBI-induced BBB 
hyperpermeability and brain edema.  
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INTRODUCTION 
 Brain endothelial hyperpermeability that occurs at the level of the blood-brain 
barrier (BBB) is a common secondary injury that occurs as a consequence of various 
traumatic injuries to the brain, including traumatic brain injury (TBI).  
Hyperpermeability can be defined as the leakage of fluid and proteins into the 
extravascular space leading to vasogenic edema [126] with several adverse clinical 
consequences leading to patient death. Thus, understanding the mechanisms that are 
involved in the loss of BBB integrity leading to hyperpermeability is critical for 
therapeutic drug development against TBI. The integrity and permeability of the BBB is 
dictated mainly by the tight junctions (TJ) between the inter-endothelial cells [63] as 
they make up the structural and functional units of the BBB. Tight junctions proteins 
can be transmembrane in nature like occludin, claudins, junctional adhesion molecules 
or membrane bound, as in the case of zonula occludens proteins (ZOs) [63]. Among the 
ZOs, Zonula occludens-1 is an important scaffolding linker molecule in the BBB that 
binds to both transmembrane TJPs and actin cytoskeletal assembly intracellularly. BBB 
breakdown is a hallmark feature of the secondary injuries that occur following TBI.  
 Traumatic brain injury is the leading cause of mortality and morbidity 
worldwide. Annual incidence of TBI is accounted to be around 10 million people 
worldwide, with 5.3 million people from US alone, based on 2010 CDC statistics [63]. 
Accumulation of ATP metabolites in the cerebrospinal fluid correlates with edema 
formation and elevated intracranial pressure (ICP) as observed in a neurotrauma patient 
[127]. TBI is followed by depletion in cellular ATP [128]. Several evidences also 
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support the release of ATP from injured cells following trauma and TBI [129; 130; 131; 
132].  
 ATP is essential for all living cells as a source of energy but when released 
extracellularly it acts in autocrine and paracrine fashion via purinergic receptors (P1 and 
P2) [9; 133; 134; 135]. Adenosine molecules activate P1 receptors, while ADP/ATP 
activates P2 receptors [136]. Purinergic receptors can be of two types: P2X (ligand-
gated ion channels) and P2Y (G-protein coupled receptors) [133; 137; 138]. Studies by 
Gorodeski et al, 1997 demonstrate the role of extracellular ATP in regulating 
permeability in human cervical epithelial cells [139]. However, no information is 
currently available on the study of the role of ATP in the context of BBB dysfunction 
and hyperpermeability.  
Extracellular ATP acts via purinergic receptor, P2X7 receptors (P2X7R) and are 
activated by high concentrations of ATP, usually >100 μM [140]. P2X7Rs exhibit low 
sensitivity to ATP and bind preferentially to Bz-ATP (2'(3')-O-(4-Benzoylbenzoyl) 
adenosine-5'-triphosphate tri (triethylammonium) salt) [134; 136]. Beneficial effects of 
P2X7R inhibition following neurotrauma are also studied [130; 141]. However, these 
studies do not aim to study the effect of P2X7R inhibition on TBI-induced BBB 
dysfunction and hyperpermeability. We hypothesize that P2X7R-mediated mechanisms 
play an important role in regulating ATP-induced BBB dysfunction and 
hyperpermeability. We investigated this hypothesis, by addressing the following 
questions: 
 What is the effect of Bz-ATP treatment on BBB endothelial hyperpermeability? 
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 What is the effect of P2X7R inhibition on Bz-ATP-induced endothelial 
hyperpermeability, tight junction integrity and actin stress fiber formation.  
 Does Bz-ATP treatment alter cell viability or alter ZO-1 mRNA or protein 
expression? 
 What is the effect of TBI on BBB integrity in P2X7R global knockout mice?  
 Can a pharmacological inhibitor of P2X7R such as KN-62 decrease TBI-induced 
BBB hyperpermeability?  
 
 
MATERIALS AND METHODS 
Materials 
Rat brain microvascular endothelial cells (RBMECs) and Rat Brain Endothelial 
Cell Growth Medium were purchased from Cell applications, Inc. (San Diego, CA). 
Human brain microvascular endothelial cells (HBMECs) and CSC Complete Medium 
(containing CultureBoost-R and Bac-Off®), Attachment Factor were purchased from 
Cell systems (Kirkland, WA). Transwell® 24-well plates were obtained from Corning 
Costar (New York, USA). Nunc Lab Tek II-CC, 8-well glass chamber slides, 2′ (3′)-O-
(4-Benzoylbenzoyl)adenosine 5′-triphosphate triethylammonium salt (Bz-ATP), 
fibronectin from bovine plasma, β-actin, albumin from bovine serum, Evans blue, 
trichloroacetic acid, fluorescein isothiocyanate-dextran-10 kDa were purchased from 
Sigma Aldrich (St. Louis, MO). Rabbit anti ZO-1 (Cat # 617300), mouse anti ZO-1 (Cat 
# 339100), 0.25% Trypsin (1X), Opti-MEM (1X)/reduced serum medium, Dulbecco's 
modified Eagle‟s medium (DMEM; with high glucose, HEPES, no phenol red (1X)), 
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NuPAGE Novex® 10% Bis-Tris protein gels, NuPAGE® MOPS SDS Running Buffer, 
NuPAGE® Transfer Buffer, HyClone Dulbecco's phosphate buffered saline (PBS, 
without calcium, magnesium, or phenol red), TRIzol® Reagent, SuperScript® IV First-
Strand Synthesis System, Halt® Protease Inhibitor Cocktail (100X), Pierce™ ECL 
Western Blotting substrate and rhodamine phalloidin were purchased from Thermo 
Fisher Scientific (Carlsbad, CA). Goat anti-mouse IgG-HRP and donkey anti-rabbit 
IgG-FITC secondary antibodies were purchased from Santa Cruz Biotechnology, Inc. 
(Santa Cruz, CA). EZViable™ Calcein AM Cell Viability fluorometric assay kit was 
bought from Biovision (Milpitas, CA). We also purchased Vector VECTASHIELD® 
Mounting Media with DAPI from Vector Laboratories (Burlingame, CA). Pierce™ 
BCA Protein Assay Kit and RT² qPCR Primer Assay for Mouse GAPDH were 
purchased from Qiagen (Valencia, CA). Cell Lysis Buffer (10X) was bought from Cell 
Signaling Technology, Inc. (Danvers, MA). Primers were purchased from Thermo 
Fisher Scientific (Carlsbad, CA). P2X7R siRNA and control siRNA (ON-TARGETplus 
siRNA) were purchased from Dharmacon, General Electric (Pittsburgh, PA). A740003 
and KN-62 was purchased from Tocris Biosciences (Minneapolis, MA). 
In vitro BBB model 
Primary cultures of RBMECs derived from the brain of adult Sprague Dawley 
rat were purchased from the Cell Applications Inc. (San Diego, CA). RBMECs were 
initially grown on 0.05% fibronectin-coated cell culture dishes, using the RBMEC 
medium in a cell culture incubator (95% O2, 5% CO2 at 37°C). Primary cultures of 
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HBMECs derived from the normal human brain cortex were purchased from the Cell 
systems (Kirkland, WA). HBMECs were initially grown on attachment factor-coated 
cell culture dishes using CSC complete medium in a cell culture incubator (95% O2, 5% 
CO2 at 37°C). RBMECs and HBMECs were treated with 0.25% trypsin-EDTA for cell 
detachment. Detached cells were then grown on fibronectin/attachment factor-coated 
Transwell® inserts, chamber slides or 100 mm dishes for experimental purposes. 
RBMEC/HMBEC passages 5-10 were chosen for all the experiments.  
 
 
Animals and surgeries 
C57BL/6 mice (25-30 g) were purchased from Charles River Laboratories 
(Wilmington, MA). P2X7R knockout animals (male and female) were bought from 
Jackson Laboratories (Boston, MA) and bred at Texas A&M Institute for Genomic 
Medicine facility. C57BL/6 animals were maintained at the Texas A&M University 
Health Science Center College of Medicine and Baylor Scott and White Health animal 
facility on a 12:12 hour dark/light cycle, with free access to food and water. The room 
temperature was maintained at 25° ± 2°C. Surgical and experimental procedures used in 
this study were conducted after approval by the Institutional Animal Care and Use 
Committee. The facility is approved by the Association for Assessment and 
Accreditation of Laboratory Animal Care International in accordance with the National 
Institutes of Health guidelines.  
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Craniotomy procedure 
The head of the animal was shaven and the surgical site on the surface of the 
head was cleaned with an alcohol wipe. Lubricating ointment was applied to the eyes. 
Midline incision on the scalp helps to remove the skin from top of the skull exposing the 
sagittal suture, bregma and lambda. A circular craniotomy window, 3-4 mm in diameter 
was made on ipsilateral hemisphere, between lambda and bregma using a microdrill. 
The resulting bone flap was removed. Sham animals received only craniotomy surgery, 
while TBI injury group receives brain injury via controlled cortical impactor following 
craniotomy procedure. 
 
 
Controlled cortical impactor 
These studies employ Benchmark™ Stereotaxic Impactor from Leica, for 
inflicting the TBI in mice. Following craniotomy procedure as described above, the 
animal was then mounted on the stereotaxic frame. An impactor probe of 3 mm 
diameter was used to impact the exposed part of the brain. The depth of the injury was 
used to determine the intensity of the injury. Settings for mild TBI used in this study 
are: 2 millimeters depth, 0.5 meters/second velocity and 100 milliseconds contact time 
as described in Chen et al, 2014 [88]. 
 
 
Treatments 
KN-62 at a dose of 10 mg/kg was used for acute drug administration studies. 
This dose was chosen based on the studies done in rats, which demonstrated that 
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intravenous injection of KN-62 at 10 mg/kg, did not alter systemic arterial pressure of 
heart rate [142] and hence was a reasonable choice for our mice studies in vivo. KN-62 
is a non-competitive antagonist of the P2X7R receptor, which also binds directly to the 
calmodulin binding site of the CaMKII (calcium-calmodulin-dependent protein kinase 
type II). KN-62 was administered via the tail vein along with Evans blue injection and 
allowed to circulate for 30 minutes prior to TBI.  
 
 
Monolayer permeability assays 
HBMECs or RBMECs were grown on fibronectin-coated Transwell® inserts as 
monolayers for 72-96 hours and regularly checked for confluency. Monolayers were 
initially exposed to phenol red free DMEM for 45 minutes to an hour. DMEM treated 
cells were then pretreated with P2X7R inhibitor, A740003 (100 μM; 30 minutes) and 
subsequently with Bz-ATP. At the end of the study, FITC labeled dextran-10 kDa (5 
mg/mL; 30 minutes) was applied to the luminal compartment. One hundred microliters 
of sample was collected from the abluminal compartment at the end of 30 minutes and 
measured fluorometrically at 485 nm/520 nm (Excitation/Emission) using Fluoroskan 
Ascent™ FL Microplate Fluorometer and Luminometer (Vantaa, Finland).  
Preliminary studies in HBMECs employed Bz-ATP treatment at a concentration 
of 5 mM for an hour. This experiment was repeated six times. In a separate set of 
experiments, minimal dose of Bz-ATP treatment to induce RBMEC monolayer 
hyperpermeability was determined. In this procedure, RBMECs were exposed to phenol 
red free DMEM for 45 minutes to an hour following which they were treated with 
 100 
 
different concentrations of Bz-ATP ranging from 10 to 250 μM for 4 hours. Minimal 
dose of Bz-ATP treatment to induce RBMEC monolayer hyperpermeability was 
obtained. This information was then used to test the effect of P2X7R antagonist, 
A740003 (100 μM; 30 minutes) on Bz-ATP treatment-induced RBMEC monolayer 
hyperpermeability. These experiments were repeated four times.  
Untreated cells served as a control group. Fluorescence intensity was plotted on 
the Y-axis and represented as % control. Data were expressed as mean ± % SEM and 
statistical differences among groups were determined by one-way analysis of variance 
(ANOVA) followed by Bonferroni post hoc test to determine significant differences 
between specific groups. A value of p<0.05 was considered statistically significant. 
 
 
P2X7R knockdown studies 
RBMECs were grown on fibronectin-coated Transwell® inserts for 24 hours and 
transfected with P2X7R and control siRNA at 25 nM concentration for 72 hours. 
Transfection was performed according to manufacturer‟s instructions. Transfected 
monolayers were then exposed to Bz-ATP (10 μM; 4 hours) and permeability was 
determined based on the leakage of FITC-dextran-10 kDa (5 mg/mL; 30 minutes) 
leakage from the luminal to the abluminal chamber. One hundred microliters of the 
sample was obtained from the abluminal chamber and measured fluorometrically at 
485/520 nm (Excitation/Emission) using Fluoroskan Ascent™ FL Microplate 
Fluorometer and Luminometer. 
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Untreated cells were maintained as a control group. Each experiment was 
repeated five times. Fluorescence intensity was plotted on the Y-axis and represented as 
% control. Data were expressed as mean ± % SEM and statistical differences among 
groups were determined by one-way analysis of variance (ANOVA) followed by 
Bonferroni post hoc test to determine significant differences between specific groups. A 
value of p<0.05 was considered statistically significant. 
 
 
Immunofluorescence localization and cytoskeletal labeling  
In order to study tight junction integrity, ZO-1 junctional localization and 
formation of f-actin stress fibers were assessed. RBMECs were grown on chamber 
slides for overnight. The cells were pretreated with A740003 (100 μM; 30 minutes) 
followed by Bz-ATP (10 μM; 4 hours) treatment. The cells were then fixed in 4% 
paraformaldehyde in PBS for 10-15 minutes and permeabilized with 0.5% Triton-X 100 
in PBS for another 10-15 minutes. Following this, the cells were blocked with 2% 
bovine serum albumin (BSA) in PBS for an hour at room temperature. The cells were 
then incubated overnight in an anti-rabbit primary antibody against ZO-1 (#617300; 
1:150) in 2% BSA-PBS, followed by incubation with anti-rabbit IgG-FITC conjugated 
secondary antibody for an hour at room temperature. The cells were then washed and 
mounted using VECTASHIELD® Antifade Mounting Media with DAPI for nuclear 
staining.  
Following this, the cells were fixed, permeabilized and blocked in 2% BSA-PBS 
as described earlier. The cells were then labeled with rhodamine phalloidin (1:50) in 2% 
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BSA-PBS for 20 minutes, washed and mounted using VECTASHIELD® Antifade 
Mounting Media containing DAPI for nuclear staining.  
RBMECs were visualized and scanned at a single optical plane with an Olympus 
Fluoview 300 Confocal Microscope (Center Valley, PA) with a PLA PO 60X water 
immersion objective. Untreated cells served as control. Each experiment was repeated 
four times.  
 
 
Quantitative real time-PCR 
RBMECs were grown on 100 mm cell culture dishes. The total RNA was then 
extracted using TRIzol® reagent according to the manufacturer‟s instructions. RNA 
concentration and quality were determined by employing the ratio of absorbance at 
260/280 nm using Biotek Synergy Hybrid Spectrophotometer (Winooski, VT).  Reverse 
transcription was performed using the SuperScript® IV First-Strand Synthesis System. 
Quantitative real time PCR was performed using the RT² SYBR Green Fluor qPCR 
Mastermix with the following primer pairs for ZO-1: Forward primer: 5′-
CCTCTGATCATTCCACACAGTC-3′, Reverse primer: 5′-
TAGACATGCGCTCTTCCTCTCT-3′, MMP-9: Forward primer: 5'-
GGCTAGGCTCAGAGGTAA-3', Reverse primer: 5'-GACGTTGTGTGAGTTCCAG-
3' and GAPDH: Forward primer: 5′-AATGTATCCGTTGTGGATCT-3′, Reverse 
primer: 5′-CAAGAAGGTGGTGAAGCAGG-3′ were used. Real-time PCR detection 
was carried out using Stratagene Mx3000P qPCR System, Agilent Technologies (La 
Jolla, CA), using 1 μL of cDNA for 10 minutes at 95°C, followed by 40 cycles of 15 sec 
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at 95°C for denaturation and 1 min at 60°C for annealing. Relative abundances of target 
genes were calculated by normalizing Ct values to endogenous control glyceraldehyde 
3-phosphate dehydrogenase (GAPDH). 
Cells were divided into control (untreated), B-ATP (10 μM; 4 hours) treatment 
alone, pretreatment with A740003 (100 μM; 30 minutes) followed by Bz-ATP (10 μM; 
4 hours) and A740003 (100 μM; 30 minutes) alone. Each experiment was repeated three 
times. Relative mRNA expression of ZO-1 was obtained by normalizing the Ct values to 
the endogenous control GAPDH for each repeat. Normalized Ct values were expressed 
as mean ± SEM. Statistical differences among groups were determined by one-way 
analysis of variance (ANOVA) followed by Bonferroni post hoc test to determine 
significant differences between specific groups. A value of p<0.05 was considered 
statistically significant. 
 
 
Western blot assays 
Western blot analysis was performed to investigate expression of ZO-1 in 
RBMECs. Cells were divided into control (untreated) and Bz-ATP (10 μM; 4 hours) 
treatment groups. Following treatments, the cells were washed twice in ice-cold PBS 
and incubated in ice-cold cell lysis buffer (1X) along with protease inhibitor cocktail 
(1X) for 5 minutes in cell culture dishes. The cells were then scraped, sonicated and 
centrifuged at 14,000g for 10 minutes at 4C. Supernatant was collected from the 
extracts and protein concentration was determined using a protein assay kit. Equal 
amounts of total protein (50 μg) were separated by sodium dodecyl sulphate-
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polyacrylamide gel electrophoresis (SDS-PAGE) on 10% Bis-Tris precast gels at 
constant voltage (145 V) for 180 minutes. Proteins were then transferred onto the 
nitrocellulose membrane at constant voltage (30 V) for overnight and the membranes 
were blocked using 5% nonfat dry milk in Tris-Buffered Saline (TBS) with 0.05% 
Tween-20 for 3 hours and subsequently incubated with primary mouse monoclonal anti 
ZO-1 antibody (1:250 dilution). Membranes were washed thrice in TBS-T and 
incubated with a goat anti-mouse IgG-HRP conjugated secondary antibody for an hour. 
After washing, the immunoblots were visualized by ECL Western Blotting Substrate. 
Untreated cells served as control. The loading of equal amount of protein sample was 
verified by assessing β-actin protein expression used as an internal control. Each 
experiment was repeated four times. 
 
 
Cell viability studies 
An EZViable™ Calcein AM Cell Viability Assay Kit (Fluorometric) was used 
to quantify the number of viable cells. Calcein AM is a non-fluorescent, hydrophobic 
compound that easily penetrates intact and live cells. Hydrolysis of the calcein AM by 
intracellular esterase produces a hydrophilic, strongly fluorescent compound that is 
retained in the cell cytoplasm, which can be measured at 485/530 nm 
(Excitation/Emission).  
For this study, equal numbers of RBMECs were grown on a sterile black 96 well 
trays. When the cells reached confluency, growth media was discarded and the cells 
were washed in PBS and pre-exposed to phenol red-free medium for 1 hour. Cells were 
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divided into control (untreated), Bz-ATP treatment at 10 and 50 μM for 4 hours. 
Hydrogen peroxide (100 μM; 4 hours) was used as a positive control. Following 
treatments, the cells were then exposed to calcein buffer solution (calcein AM: calcein 
dilution buffer in 1:500 dilution) and incubated at 37C for 30 minutes and a 
fluorometric reading was obtained.  
Each experiment was repeated five times. Fluorescence intensity was plotted on 
the Y-axis and represented as % control. Data were expressed as mean ± % SEM and 
statistical differences among groups were determined by one-way analysis of variance 
(ANOVA) followed by Bonferroni post hoc test to determine significant differences 
between specific groups. A value of p<0.05 was considered statistically significant. 
 
 
Intravital microscopy imaging  
C57BL/6 mice (25-30 g) were anesthetized with urethane, i.p. injection (2 
mL/kg body weight) followed by FITC-dextran-10 kDa, i.v. injection (50 mg/mL; 100 
μL). FITC-dextran was allowed to circulate in the animal for 5 minutes prior to 
performing sham surgery (only craniotomy) or TBI using a controlled cortical impactor. 
Surgical site was then cleaned and a cover glass was placed on the surgical site with the 
help of super glue. The animal was then placed under a Nikon intravital microscope  
and the images were captured at 30, 50, and 70 minutes using a 40X objective. Vessels 
ranging from 20-40 μm were only chosen for imaging pial microcirculation using FITC 
imaging cube with emission wavelength of 525 nm.  
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FITC-fluorescence intensity values were obtained by choosing a small region in 
the intravascular (Ii) and extravascular space (Io) and dividing it by the area. The ratio 
of average extravascular to intravascular FITC-intensity values were obtained and 
normalized to the baseline ratio obtained at 30 minutes and plotted on the Y-axes. Mean 
± SEM at different time points 30, 50 and 70 minutes were plotted on the X-axis. Each 
group consisted of five animals. Statistical differences among groups were determined 
by two-way analysis of variance (ANOVA) followed by Bonferroni post hoc test to 
determine significant differences between specific groups. Significant differences 
between the specific groups were further confirmed by repeated measures ANOVA for 
95% confidence interval followed by Tukey post hoc test. If the 95% confidence 
interval does not overlap with 0, then the difference between group means is significant 
as seen for the comparisons between WT-sham and WT-TBI animals or WT-TBI and 
KO-TBI animals. A value of p<0.05 was considered statistically significant. 
 
 
Evans blue extravasation assays 
Evans blue dye binds to the albumin in the blood enabling us to study vascular 
leakage into the extravascular tissue following TBI when the dye is extracted and 
measured fluorometrically. C57BL/6 mice (25-30 g) were anesthetized with urethane, 
i.p. injection (2 mL/kg body weight) followed by Evans blue dye, i.v. injection (2% 
wt/vol in saline; 4 mL/kg body weight). Evans blue was allowed to circulate in the 
animal for 30 minutes prior to performing sham surgery (only craniotomy) or TBI using 
controlled cortical impactor. Drug was given to the animal along with Evans blue 
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injection and allowed to circulate for 30 minutes as well. DMSO was used a vehicle 
control. Settings for mild TBI are given in the CCI procedure described above.  
 One-hour post-TBI, animals were transcardially perfused with sterile saline 
containing heparin (1000 U/mL) for at least 20 minutes. Brains were extracted and brain 
cortex was carefully separated and weighed. Brain cortices were then homogenized in 1 
mL of 50% (wt/vol) trichloroacetic acid (TCA) in saline. Homogenate was then 
centrifuged at 6,000g for 20 minutes at 4C. Supernatants were extracted and further 
diluted in 3 parts of ethanol (1:3; 50% TCA: 95% ethanol). Samples were then 
quantitated fluorometrically at 620/680 nm (Excitation/Emission) or colorimetrically at 
610 nm using Biotek Synergy Hybrid H1 spectrophotometer (Winooski, VT). Evans 
blue amount in the samples was evaluated using external standards for Evans blue 
ranging from 50-1000 ng/mL, prepared in same solvent (1:3; TCA: 95% ethanol).  
To study the effect of P2X7R gene deletion on TBI-induced BBB 
hyperpermeability, in the initial studies, P2X7R-/- and wild type animals were subjected 
to TBI as described above. Each group consisted of four animals. Statistical differences 
among the groups were determined by student‟s t-test. Later studies employed P2X7R-/- 
and wild type animals, which were then divided into sham (only craniotomy) and mild 
TBI injury groups. In this study each group consisted of nine animals. Statistical 
differences among groups were determined by one-way analysis of variance (ANOVA) 
followed by Bonferroni post hoc test to determine significant differences between 
specific groups. A value of p<0.05 was considered statistically significant. 
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In order to study, the effect of a pharmacological inhibitor of P2X7R on TBI-
induced BBB hyperpermeability, the drug KN-62 was used. For these studies, animals 
were grouped into a sham (only craniotomy), a Vehicle + Sham group (DMSO vehicle 
injection followed by craniotomy), a Vehicle + TBI group (DMSO vehicle injection 
followed by mild TBI), and a KN-62 + TBI group (KN-62 [10 μg/gram body weight] 
followed by mild TBI). Each group consisted of five animals. Brain tissue was 
collected, extracted and the amount of Evans blue dye was measured as described 
above. Evans blue amount in the samples were expressed as ng/per brain cortex ± SEM. 
Statistical differences among groups were determined by one-way analysis of variance 
(ANOVA) followed by Bonferroni post hoc test to determine significant differences 
between specific groups. A value of p<0.05 was considered statistically significant. 
 
 
RESULTS 
P2X7R inhibition attenuates Bz-ATP-induced endothelial cell hyperpermeability 
RBMEC monolayers were pretreated with P2X7R inhibitor, A740003 (100 μM; 
30 minutes) to confirm the contribution of P2X7R in mediating Bz-ATP (5 mM; 1 
hour)-induced endothelial cell hyperpermeability. Bz-ATP treatment increased 
monolayer hyperpermeability significantly, while pretreatment with A740003 
significantly attenuated Bz-ATP-induced hyperpermeability (p <0.05; Figure 26). 
Permeability was assessed by monolayer permeability assays as described earlier. This 
experiment was performed in HBMECs as preliminary studies to confirm the 
hypothesis. Each experiment was repeated six times. 
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Figure 26: A740003 pretreatment attenuates Bz-ATP treatment-induced monolayer 
hyperpermeability in HBMECs (n=6; p<0.05). Monolayer permeability is expressed as a 
percentage control of FITC-dextran-10 kDa fluorescence intensity, plotted on the Y-
axis. Data are expressed as mean ± % SEM. „*a‟ indicates significant increase compared 
to the control; „*b‟ indicates significant decrease compared to the Bz-ATP treatment 
group. 
Bz-ATP treatment induces endothelial cell monolayer hyperpermeability, alters 
ZO-1 junctional localization, and decreases ZO-1 protein expression 
Rat brain endothelial cell monolayers were treated with Bz-ATP at different 
concentrations varying from 10 μM to 250 μM for 4 hours. Bz-ATP treatment 
significantly increased endothelial cell hyperpermeability from 10 μM up to 250 μM (p 
<0.05; Figure 27 A).  Hyperpermeability was evidenced by the increase in the FITC-
dextran-10 kDa leakage to the lower chamber of the Transwell® insert. Four hours of 
Bz-ATP treatment was chosen as the earlier time point to induce monolayer 
hyperpermeability (2-3 hours did not show any significant increase in permeability from 
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our preliminary studies). Based on this information, we employed Bz-ATP treatment at 
10 μM concentration for 4 hours in RBMECs. 
In order to study the changes in integrity of BBB tight junctions, 
immunofluorescence of tight junction protein, ZO-1 was performed following Bz-ATP 
treatment. Bz-ATP (10 μM; 4 hours) treatment induced ZO-1 junctional discontinuity 
(white arrows; Panel 27 B) and decreased ZO-1 protein expression (Panel 27 C) 
compared to the untreated control cells. 
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Figure 27: Bz-ATP treatment induces monolayer hyperpermeability, ZO-1 junctional 
disruption and decreases ZO-1 protein expression. Monolayer permeability was 
expressed as a percentage control of FITC-dextran-10 kDa fluorescence intensity, 
plotted on the Y-axis (figure A; n=4). Data are expressed as mean ± % SEM. „*a‟ 
indicates significant increase compared to the control group. p<0.05 is considered as 
statistically significant.  
Bz-ATP treatment-induced ZO-1 junctional disruption is demonstrated by 
immunofluorescence localization of ZO-1 (figure B; n=4). Bz-ATP treatment reduces 
total ZO-1 protein expression as shown by western blot studies in rat brain endothelial 
cells (figure C; n=4).  
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P2X7R inhibition attenuates Bz-ATP-induced endothelial cell hyperpermeability 
Bz-ATP (10 μM; 4 hours) treatment-induced endothelial cell monolayer 
hyperpermeability significantly, while pretreatment with A740003 (100 μM; 30 
minutes) attenuated Bz-ATP-induced hyperpermeability significantly (p <0.05; Figure 
28).  
Figure 28: A740003 pretreatment attenuates Bz-ATP treatment-induced monolayer 
hyperpermeability in RBMECs (n=4; p<0.05). Monolayer permeability is expressed as a 
percentage control of FITC-dextran-10 kDa fluorescence intensity, plotted on the Y-
axis. Data are expressed as mean ± % SEM. „*a‟ indicates significant increase compared 
to the control group; „*b‟ indicates significant decrease compared to the Bz-ATP 
treatment group. 
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P2X7R knockdown attenuates Bz-ATP-induced endothelial cell hyperpermeability 
Bz-ATP (10 μM; 4 hours) treatment-induced monolayer hyperpermeability was 
blocked in P2X7R transfected (25 nM; 72 hours) monolayers (Figure 29, p <0.05). 
Figure 29: Knockdown of P2X7R by siRNA attenuates Bz-ATP treatment-induced 
monolayer hyperpermeability (n=5; p<0.05). Monolayer permeability is expressed as a 
percentage control of FITC-dextran-10 kDa fluorescence intensity, plotted on the Y-
axis. Data are expressed as mean ± % SEM. „*a‟ indicates significant increase compared 
to the control group; „*b‟ indicates significant increase compared to the control siRNA 
treatment group and „*c‟ indicates significant decrease compared to the control siRNA+ 
Bz-ATP treatment group.  
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P2X7R inhibition protects against Bz-ATP-induced loss of tight junction integrity 
and f-actin stress fiber formation 
RBMECs were processed for immunofluorescence localization of tight junction 
protein, ZO-1. Bz-ATP treatment (10 μM for 4 hours and 5 mM for 1 hour)-induced 
ZO-1 junctional discontinuity (white arrows; Panel 30 A and B) compared to the control 
cells. Pretreatment with A740003 (100 μM; 30 minutes) decreased Bz-ATP-induced 
loss of ZO-1 at the tight junctions. Panel A represents the data from higher 
concentration of Bz-ATP and panel B represents the data from lower concentration of 
Bz-ATP 
 For studying the changes in actin cytoskeletal assembly, rhodamine phalloidin 
labeling technique was performed. Bz-ATP (10 μM for 4 hours and 5 mM for 1 hour) 
treatment-induced f-actin stress fiber formation (white arrows; Figure 30 C and D) was 
reduced following pretreatment with A740003 (100 μM; 30 minutes). The data from the 
high concentration of Bz-ATP treatment (5 mM; 1 hour) is shown in the Figure 30, 
panel C, while panel D shows data from the study where Bz-ATP treatment at 10 μM 
was done for 4 hours. 
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Figure 30: Bz-ATP treatment-induced ZO-1 junctional disruption and f-actin stress 
fiber formation is reduced by pretreatment with A740003. Immunofluorescence 
localization of ZO-1 (panel A and B) and rhodamine phalloidin labeling of actin 
cytoskeleton (panel C and D) are shown in the figure. Bz-ATP treatment-induced ZO-1 
junctional disruption (white arrows; panel A and B; n=4) and f-actin stress fiber 
formation (white arrows; panel C and D; n=4) were preserved on pretreatment with 
A740003. Five millimolar of Bz-ATP treatment for an hour is shown in panel A and C; 
10 μM Bz-ATP treatments for 4 hours are shown in panel C and D.  
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Bz-ATP treatment does not induce ZO-1 mRNA expression 
RT-PCR study showed that Bz-ATP treatment at 10 μM for 4 hours did not alter 
ZO-1 or MMP-9 mRNA expression (Figure 31). 
Figure 31: Bz-ATP treatment does not induce ZO-1 mRNA expression. RT-PCR data 
are expressed as relative expression of ZO-1 normalized to GAPDH is plotted on Y-
axis. Data are represented as mean ± SEM (n=3). 
Bz-ATP treatment does not induce cell death in endothelial cells 
Bz-ATP treatment at 10 μM for 4 hours did not cause any significant change in 
the number of viable cells as shown in Figure 32. Hydrogen peroxide (100 μM; 4 hours) 
used as a positive control decreased cell viability significantly. 
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Figure 32: Bz-ATP treatment does not affect cell viability. Hydrogen peroxide was 
used as a positive control (n=5; p<0.05). Cell viability is expressed as a percentage 
control of fluorescence intensity, plotted on the Y-axis. Data are expressed as mean ± % 
SEM. „*a‟ indicates significant decrease compared to the control group.  
Genetic ablation of P2X7R provides protection against TBI-induced FITC-dextran 
leakage 
The effect of TBI-induced FITC-dextran-10 kDa (50 mg/mL) leakage in pial 
microvasculature of P2X7R -/- and wild type animals was assessed using intravital 
microscopy imaging as described above. Mice were studied at various time points (30, 
50, and 70 minutes as shown in Figure 34) following TBI/sham injury. The wildtype 
mice subjected to TBI showed a significant increase in FITC-dextran extravasation 
compared to P2X7R -/- mice. p<0.05, n=5, Figure 34). 
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Figure 33: Effect of TBI on BBB permeability (studied by FITC-dextran leakage) in 
P2X7R knockout mice. Figure A demonstrates that P2X7R knockout animals subjected 
to TBI show a decrease in FITC-dextran-10 kDa leakage into the extravascular space of 
the pial vessel compared to the wild-type animals (shown by white arrows) subjected to 
TBI. Quantitative representation of FITC-fluorescence intensity values are shown in 
Figure B. Figure C represents the statistical analysis by repeated measures ANOVA 
using 95% confidence intervals, followed by Tukey HSD post hoc test for the FITC-
fluorescence intensity values.  Images using intravital microscopy were taken at 30, 50, 
and 70 minutes after inducing TBI. Each group had five animals. Ratio of FITC-
dextran-10 kDa in the extravascular space to intravascular space relative to 30 minutes 
baseline is plotted on Y-axis. Data are expressed as mean FITC-fluorescence intensity ± 
SEM. „*a‟ indicates significant increase compared to the WT-sham injury group within 
the time point, „*b‟ indicates significant decrease compared to the WT-TBI group 
within the time point. 
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Genetic ablation of P2X7R provides protection against TBI-induced Evans blue 
leakage 
Effect of TBI-induced Evans blue leakage was studied in P2X7R -/- knockout 
and wild type mice using the Evans blue extravasation assays as described earlier. 
Evans blue leakage was assessed colorimetrically at 610 nm. TBI-induced BBB 
hyperpermeability was significantly attenuated in P2X7R -/- mice compared to wild 
type mice (Figure 33 A & B, p<0.05). 
Preliminary studies were performed using only four animals as shown in figure 
33 A. A thorough study using all groups with nine animals per group is shown in figure 
33 B. 
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Figure 34: Effect of TBI on BBB permeability (studied by Evans blue leakage) in 
P2X7R knockout mice. P2X7R knockout mice demonstrated significantly reduced 
Evans blue leakage compared to the wild-type animals subjected to the TBI (figure A; 
n=4; p <0.05). Figure B shows the results of a separate study that further confirms the 
results in Figure A (n=9; p <0.05). Data are expressed as absorbance ± SEM. „*a‟ in 
figure A represents significant decrease compared to the wild type animals subjected to 
TBI. „*a‟ in figure B indicates significant increase compared to the wild-type sham 
animals; „*b‟ indicates significant decrease compared to wild-type animals subjected to 
TBI.  
KN-62 pretreatment attenuates TBI-induced BBB hyperpermeability 
Mice subjected to TBI demonstrated significant increase in Evans blue leakage 
compared to the sham animals. Pretreatment with KN-62 attenuated mild TBI-induced 
Evans blue leakage into the brain tissue (Figure 35 A & B; p <0.05). Evans blue leakage 
was assessed fluorometrically at 620/680 nm (Excitation/Emission). This study suggests 
that P2X7R inhibition as a potential drug target against BBB hyperpermeability that 
occurs following TBI. 
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Figure 35: KN-62 pretreatment attenuates TBI-induced BBB hyperpermeability studied 
by Evans blue dye extravasation method. Vehicle control group subjected to TBI 
demonstrated significant increase in Evans blue leakage compared to the sham injury 
group (figure A; p<0.05). KN-62 (10 μg /gram body weight of the animal) pretreatment 
significantly attenuated TBI-induced Evans blue leakage into the extravascular tissue 
space (figure A; p<0.05). Pictorial representation of the brain tissue from various groups 
is shown in figure B. Each group consisted of five animals. Sham injury group is used 
as the baseline for all comparisons. Data are expressed as ng/brain cortex ± SEM. „*a‟ 
indicates significant increase compared to the sham injury group, „*b‟ indicates 
significant decrease compared to the vehicle + TBI group.  
122 
DISCUSSION 
The major findings of this study are: 1) extracellular ATP induces the loss of 
tight junctional integrity, enhances f-actin stress fiber formation and BBB 
hyperpermeability via P2X7R receptors in vitro, 2) ATP/P2X7R-mediated loss of 
barrier function involves a decrease in ZO-1 protein expression but not mRNA 
expression and is independent of endothelial cell death, and 3) genetic and 
pharmacological inhibition of P2X7R provides protection against TBI-induced BBB 
hyperpermeability in a mouse model of TBI. 
ATP is traditionally known as the energy source of the cell that drives all the 
cellular functions. Various pathological conditions like inflammation, ischemia and 
trauma lead to an increase in extracellular ATP [132]. ATP plays an important role in 
inflammation by aiding in the processing and release of pro-inflammatory cytokines like 
IL-1β and IL-6 [133]. However, the effect of ATP on IL-1β and IL-6 expression in brain 
endothelial cells are not clearly known and remains to be explored. ATP in extracellular 
space plays an important role in neurotransmission and inflammatory processes [133]. 
Millimolar concentrations of extracellular ATP are generated following local trauma 
leading to temporary increase in local nucleotide concentrations to >100 μM [143]. ATP 
is rapidly degraded in the extracellular environment by various cellular enzymes such as 
ecto-nucleotidases, ecto-nucleotide pyrophosphate, nucleotidase, phosphatases, and 
transphosphorylating enzymes like nucleoside diphosphokinase and adenylyl kinase, 
which breakdown ATP to ADP, AMP and adenosine [133; 144; 145]. Half-life of ATP 
is only a few seconds once it is released into the extracellular space, which makes its 
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detection further difficult [146]. For these reasons we employed Bz-ATP a potent and 
stable analogue of ATP in our in vitro studies. 
 ATP release that occurs following mechanical and biochemical stimulation 
regulates various cellular functions via purinergic receptors [147; 148]. P2X7R are 
involved in various cellular mechanisms like membrane permeabilization, caspase 
activation, cytokines release, cell proliferation and apoptosis [149]. The contribution of 
ATP-induced P2X7R is well studied in astrocytes, glial cells, and other immune cells of 
the brain; however, very little is known about its contribution in the brain endothelial 
cells [150]. Our results demonstrate that Bz-ATP promotes BBB hyperpermeability in 
vitro and ATP-induced hyperpermeability can be attenuated by pharmacological 
inhibition of P2X7R or by P2X7R mRNA silencing. Thus, our studies provide novel 
insight into the mechanisms by which ATP-sensitive P2X7R promote brain endothelial 
barrier dysfunction. 
 Pharmacologically, P2X7Rs are activated by high concentrations of ATP (>100 
μM) and Bz-ATP has 30 times greater potency compared to ATP. EC50 of Bz-ATP is 
~20 µM [150]. Hence, the lowest dose of Bz-ATP at a concentration of 10 μM was 
chosen in our in vitro studies. In our preliminary studies, exposure of Bz-ATP to 
endothelial monolayers for 2-3 hours did not significantly induce monolayer 
hyperpermeability. So, we chose a higher time period for Bz-ATP exposure at 4 hours. 
An interesting feature of P2X7R is its differential sensitivity across the species. For 
example, rat P2X7R are 10 fold more sensitive to Bz-ATP and ATP compared to mouse 
P2X7R [144]. Similarly, high concentrations of  extracellular ATP induces cell death 
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[151]. Hence, the ATP concentration used in a particular study should be based on the 
specific features of that study and also the source of cell types used in the study. In our 
in vitro studies we employed A740003 a potent and highly competitive antagonist of 
P2X7R that effectively blocks both human and rat P2X7 receptors [152].  
 In our in vivo studies we have used KN-62, a well-studied pharmacological 
inhibitor of P2X7R which also acts as an inhibitor of the calcium dependent enzyme 
CaMKII. Stretch-induced TBI injury in mouse brain endothelial cells demonstrated 
elevated levels of intracellular calcium levels in vitro [153]. Inhibition of intracellular 
calcium by CaMKII strongly suppresses endothelial permeability in immortalized rat 
brain endothelial cells [154]. This information was critical in our studies to determine 
the effect of KN-62 (piperazine-derived antagonist that blocks CaMKII) on TBI-
induced BBB hyperpermeability in mice. Our studies thus indicate that KN-62 
pretreatment attenuates TBI-induced BBB hyperpermeability by P2X7R and the role of 
CaMKII cannot be ruled out. The relationship between P2X7R and CaMKII pathways 
in mediating BBB dysfunction and hyperpermeability was not studied here and needs 
further investigation. 
 At a cellular level, the cytoskeleton is critical to the cellular structure and also 
regulates various signal transduction processes in endothelial cells. In previous studies, 
Bz-ATP treatment is shown to alter f-actin cytoskeletal assembly and activate various 
cellular functions like exocytosis and cell migration [155]. Our studies also 
demonstrated an increase in f-actin stress fiber formation; however, the significance of 
this increase and how it regulates various cellular functions including barrier 
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functions/permeability remains to be explored in the context of ATP-P2X7R 
interactions. Studies conducted in rat parotid acinar cells reveal that extracellular ATP 
increases the activity and phosphorylation of protein kinase D (PKD) by acting via 
P2X7R. ATP and Bz-ATP treatment (P2X7R agonist) also increases tyrosine 
phosphorylation of protein kinase-Cδ (PKCδ) and extracellular signal-regulated protein 
kinase (ERK) activity in a PKC dependent manner [156]. In addition, PKC-mediated 
alterations in ZO-1 are known. 
While our studies described in the previous chapters suggest that proteolytic 
enzymes such as MMP-9 and calpains are important in regulating barrier dysfunction, 
future studies should aim to understand the mechanisms by which ATP induces BBB 
dysfunction and hyperpermeability with a focus on specific protein kinase (C, D, etc.) or 
ERK and their relationship to P2X7R. In addition to the possibility of MMP-9 and 
calpain involvement, understanding how ATP treatment alters the phosphorylation 
status of the tight junctions may provide a rationale for the ZO-1 decrease observed in 
the present studies. 
 In conclusion, our results from in vitro and in vivo studies clearly demonstrate a 
key role for P2X7R in mediating BBB hyperpermeability. Targeting the P2X7R could 
provide a novel and promising approach for the regulation of BBB hyperpermeability 
and brain edema that occurs following TBI when established in human patients.  
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CHAPTER V 
SUMMARY AND CONCLUSIONS 
Microvascular endothelial hyperpermeability, the excessive leakage of fluid and 
proteins that takes place at the level of the blood-brain barrier (BBB) is a significant 
problem associated with various vascular conditions including traumatic, hemorrhagic 
and ischemic injuries that occur in the brain. One of the devastating injuries that occur 
in the brain is traumatic brain injury (TBI). Traumatic brain injury is the leading cause 
of death and disability worldwide in the younger population. Annual incidence of TBI is 
accounted to be around 10 million people worldwide, with 5.3 million people from US 
alone, based on 2010 CDC statistics. Thus, the basic, translational and clinical research 
that leads to deeper understanding of TBI and its pathophysiology is very critical. As 
one of the major clinical concerns in TBI is the inability to manage the TBI-associated 
brain edema and elevated intracranial pressure, focus must be given to understand the 
mechanisms that lead to brain edema formation and identification of potential 
therapeutic targets. 
Disruption of the BBB is the hallmark feature of the secondary injuries that 
occur following TBI. BBB dysfunction and the associated hyperpermeability leads to 
tissue vasogenic edema, elevated intracranial pressure, decreased tissue perfusion 
pressure, multiple organ failure, and death. Currently, there are no medications that 
could enhance BBB integrity and thereby retard the progression of secondary injuries 
following TBI. An intact BBB and optimal functioning of the BBB is critical for normal 
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brain functioning and brain homeostasis. At the cellular level, microvascular 
dysfunction of the BBB is dictated by changes in endothelial cell-cell junctions, linker 
molecules, and actin cytoskeleton. Hence, studying and understanding the contribution 
of cell adhesion molecules in BBB would provide more insight into the significance of 
altered BBB structure and functions. Our studies were focused on understanding the 
contribution of the major BBB tight junction protein, zonula occludens-1 in regulating 
BBB hyperpermeability by employing rat brain microvascular endothelial cells and TBI 
as in vitro and in vivo study models respectively. 
The two main goals of this dissertation are: 1) to understand the various cellular 
mechanisms that lead to the loss of BBB tight junction integrity leading to 
hyperpermeability and 2) to identify potential therapeutic targets against TBI-induced 
BBB dysfunction/hyperpermeability and cerebral edema. We addressed these goals by 
investigating the contribution of the proteolytic enzymes that are known to increase 
following TBI and also target TJ proteins, such as matrix metalloproteinase-9 (MMP-9) 
and calpains. Furthermore, we have investigated the role of ATP-sensitive P2X7R as an 
upstream enhancer of these pathways. Adenosine triphosphate (ATP) that is released 
into the extracellular space following trauma binds and activates P2X7R. P2X7R 
activation is further shown to activate downstream pathways that stimulate the release 
of pro-inflammatory cytokines like interleukin-1 β (IL-1β). IL-1β induces adverse 
changes in the BBB but the cellular mechanisms are not well understood. The 
proteolytic enzymes MMP-9 and calpains are also shown alter the BBB in various 
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conditions. This information served as the basis for our hypothesis, which we tested 
using various in vitro and in vivo approaches and models. 
The first mechanism presented in this dissertation (CHAPTER-II) emphasizes 
the significance of MMP-9 inhibition in regulating IL-1β treatment-induced BBB 
dysfunction and hyperpermeability. Contribution of MMP-9 was confirmed both by 
employing pharmacological MMP-9 specific inhibitors (MMP-9 inhibitor 1) and 
endogenous MMP-9 inhibitor (melatonin). Melatonin is recently explored as a potential 
MMP-9 inhibitor. Melatonin was henceforth employed to study its effect on IL-1β-
induced BBB dysfunction and hyperpermeability in vitro. Furthermore, we have also 
employed melatonin as a potential agent to attenuate TBI-induced BBB 
hyperpermeability in vivo in a mouse model of TBI. Although, our studies demonstrate 
the significance of MMP-9-mediated mechanisms in regulating BBB dysfunction and 
hyperpermeability, several questions remain unanswered. Future studies should focus on 
understanding: 1) how MMP-9 inhibition attenuates IL-1β treatment-induced 
hyperpermeability; is the via tissue inhibitors of metalloproteinases (TIMPs) or is it by 
altering the phosphorylation status of the tight junctions via various mitogen-activated 
protein kinases? 2) What is the cellular mechanism by which melatonin inhibits TBI-
induced BBB hyperpermeability other than via MMP-9 inhibition; are various MAPK 
pathways involved, and/or is the status of tight junctions altered, including ZO-1 
relocalization as found in our in vitro studies? What is the effect of melatonin on the 
well-known transcription factors of MMP-9: nuclear factor kappa-light-chain-enhancer 
of activated B cells and activator protein-1?. Although our results support melatonin-
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MMP-9 interaction as a mechanism that leads to the protection of the BBB, the multiple 
other roles of melatonin (anti-inflammatory, antioxidant, etc.) still remains to be studied 
in more detail. 
The second mechanism presented in this dissertation (CHAPTER-III) 
emphasizes the significance of calpain inhibition in regulating IL-1β treatment-induced 
BBB dysfunction and hyperpermeability. Contribution of calpains in mediating BBB 
dysfunction and hyperpermeability were studied both by employing a pharmacological 
calpain inhibitor (calpain inhibitor III) and by an endogenous calpain inhibitor 
(calpastatin). Furthermore, we have also employed calpain inhibitor III as a potential 
drug to attenuate TBI-induced BBB hyperpermeability in vivo. These studies 
demonstrate the significance of calpain-mediated mechanisms in regulating BBB 
dysfunction and hyperpermeability; several questions remain unanswered. Future 
studies should aim to address: 1) the mechanisms apart from calcium and calpastatin in 
mediating IL-1β-induced BBB hyperpermeability, 2) the main substrates for calpains in 
mediating IL-1β-induced BBB hyperpermeability, 3) whether changes in actin 
cytoskeletal assembly as observed following IL-1β treatment involve Ras homolog gene 
family, member A (RhoA), Ras-related C3 botulinum toxin substrate 1 (Rac1) and cell 
division control protein 42 homolog (cdc42), which in turn regulate tight junction 
integrity, and 4) whether there is an inter-relationship between calpains and MMP-9 
upregulation. 
The third mechanism presented in this dissertation (CHAPTER-IV) emphasizes 
the significance of P2X7R in regulating ATP-induced BBB dysfunction and 
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hyperpermeability. Contribution of P2X7R was confirmed by employing 
pharmacological inhibitors for P2X7R (A740003, KN-62). We further tested the 
importance of P2X7R by employing global knockout mice of P2X7R to study the effect 
of TBI. As hypothesized, P2X7R knockout animals demonstrated attenuated TBI-
induced BBB hyperpermeability compared to the wild-type animals. Furthermore, we 
also employed KN-62 as a potential agent to attenuate TBI-induced BBB 
hyperpermeability in vivo.  These studies demonstrate the significance of P2X7R-
mediated mechanisms in regulating BBB dysfunction and hyperpermeability; several 
questions remain unanswered. Future studies should aim to address: 1) how P2X7R-
mediated mechanisms induce the release of IL-1β in BBB; is it via inflammasome or 
caspase-1-mediated pathways? 2) How ATP binding to P2X7R affects MMP-9 or 
calpain activity in the endothelial cells as well as in in vivo models? 3) What is the 
effect of KN-62 (a P2X7R inhibitor; as well as CaMKII inhibitor) on MMP-9 and 
calpain levels in brain endothelial cells and following TBI. Pictorial representations of 
the various mechanisms and their interrelationship in regulating BBB hyperpermeability 
following brain trauma based on our studies are shown in Figure 36. 
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Figure 36: Mechanisms that regulate vascular hyperpermeability following brain 
trauma. At a structural level, the tight junctions regulate brain microvascular 
hyperpermeability. IL-1β is one of the main pro-inflammatory cytokine that is shown to 
increase following brain trauma. Our studies demonstrate that IL-1β induces matrix 
metalloproteinase-9 (MMP-9) and calpains activity, which in turn regulates vascular 
hyperpermeability by altering the tight junctional integrity. Further studies focused on 
employing pharmacological and endogenous inhibitors of MMP-9 (MMP-9 inhibitor 1, 
melatonin) and calpains (calpain inhibitor III, calpastatin) to study their effect on IL-1β-
induced BBB hyperpermeability. To elucidate the pathways upstream of IL-1β; we 
studied the effect of extracellular ATP that is known to increase following various 
traumatic insults. Extracellular ATP binds to P2X7R triggering the release of IL-1β. Our 
studies demonstrated that pharmacological inhibition of P2X7R (A740003, KN-62) can 
attenuate ATP-induced BBB dysfunction and hyperpermeability. We employed 
melatonin, calpain inhibitor III and KN-62 as potential therapeutic agents to attenuate 
TBI-induced BBB hyperpermeability. Few of the potential relationships to be explored 
for future studies include: 1) how P2X7R-mediated mechanisms induce the release of 
IL-1β in brain endothelial cells, possibly via inflammasome/caspase-1-mediated 
pathways?, 2) how ATP binding to P2X7R affects MMP-9 or calpain activity in the 
endothelial cells as well as in animal models?, and 3) how are MMP-9 and calpains 
related; i.e., do calpains activate MMP-9 or vice-versa?.  
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